

Refinement of Tools for Targeted Gene Expression in *Drosophila*

Barret D. Pfeiffer,¹ Teri-T B. Ngo, Karen L. Hibbard, Christine Murphy, Arnim Jenett,
James W. Truman and Gerald M. Rubin

Janelia Farm Research Campus, Howard Hughes Medical Institute, Ashburn, Virginia 20147

Manuscript received June 14, 2010
Accepted for publication July 30, 2010

ABSTRACT

A wide variety of biological experiments rely on the ability to express an exogenous gene in a transgenic animal at a defined level and in a spatially and temporally controlled pattern. We describe major improvements of the methods available for achieving this objective in *Drosophila melanogaster*. We have systematically varied core promoters, UTRs, operator sequences, and transcriptional activating domains used to direct gene expression with the GAL4, LexA, and Split GAL4 transcription factors and the GAL80 transcriptional repressor. The use of site-specific integration allowed us to make quantitative comparisons between different constructs inserted at the same genomic location. We also characterized a set of PhiC31 integration sites for their ability to support transgene expression of both drivers and responders in the nervous system. The increased strength and reliability of these optimized reagents overcome many of the previous limitations of these methods and will facilitate genetic manipulations of greater complexity and sophistication.

THE ability to express a gene of interest in a spatially restricted manner in a transgenic animal has greatly contributed to the use of *Drosophila* in a wide variety of biological studies. In conjunction with RNA interference and proteins that have been engineered to alter or report cell function in specific ways, directed gene expression enables the precise manipulation of the function of single cells or cell types, as well as their visualization. This ability is essential in cases such as the nervous system, where understanding function requires probing the structure and activity of individual, identified cells.

We previously described an approach for identifying a large set of enhancers that can each reproducibly drive expression of a reporter gene in a distinct, small subset of cells in the adult central nervous system (PFEIFFER *et al.* 2008). In the course of that work, we became aware of many limitations of current methods that employ the yeast GAL4 (BRAND and PERRIMON 1993; DUFFY 2002) and bacterial LexA (LAI and LEE 2006) transcription factors to drive gene expression in *Drosophila*. In this article, we report our efforts to systematically improve these widely used methods.

The GAL4 transcriptional activator from *Saccharomyces cerevisiae* functions in *Drosophila* (FISCHER *et al.* 1988), and the GAL4/UAS binary expression system

(UAS denotes a GAL4 binding site) has become a powerful and widely used tool for directed gene expression (BRAND and PERRIMON 1993; DUFFY 2002). In such two component systems, one transgenic construct drives the expression of a site-specific transcriptional activator and a second construct contains its binding sites positioned upstream of a responder gene. We evaluated many factors that affect the pattern and strength of GAL4-driven expression that had not been well characterized previously, including codon usage, transcriptional terminator, and activation domain. In addition, we show how varying the number of UAS sites or including introns or post-transcriptional regulatory elements in the UTRs influences the expression level of the target gene and the perdurance of its product. These manipulations allow the GAL4/UAS system to be tuned to adjust expression to desired levels.

The repressor LexA is a regulator of the SOS response to DNA damage in *Escherichia coli* (WALKER 1984). LexA is a 202-amino-acid protein consisting of a DNA-binding domain and a dimerization domain and binds as a dimer with varying affinities to single or multiple copies of gene-specific LexA DNA-binding motifs (LexAop) found upstream of its target genes (LITTLE and MOUNT 1982; BUTALA *et al.* 2008). Fusing a C-terminal activation domain derived from GAL4 or VP16 (SADOWSKI *et al.* 1988) to LexA allows it to drive *in vivo* transcription of reporter transgenes in *Drosophila* whose promoters contain LexAop motifs (SZUTS and BIENZ 2000; LAI and LEE 2006). Use of LexA/LexAop as a complementary binary system in conjunction with GAL4/UAS has proven useful in a variety of applications such as mosaic

Supporting information is available online at <http://www.genetics.org/cgi/content/full/genetics.110.119917/DC1>.

Available freely online through the author-supported open access option.

¹Corresponding author: Janelia Farm Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147.
E-mail: pfeifferb@janelia.hhmi.org

analysis (LAI and LEE 2006), GFP reconstitution across synaptic partners (GRASP) (FEINBERG *et al.* 2008; GORDON and SCOTT 2009), and intersectional strategies for refining gene expression patterns (SHANG *et al.* 2008). However, we found that the published LexA drivers tend to be less effective than GAL4 as transcriptional activators. Moreover, even in the absence of the LexA protein, there is detectable expression from the *colEI*-derived LexA binding sites used in the LexAop from LAI and LEE (2006). In this report we describe LexA drivers containing either the more potent extended GAL4 or human p65 (SCHMITZ and BAEUERLE 1991) activation domains and a new reporter of LexA activity that uses LexA-binding sites from *sula* (COLE 1983), another LexA target gene. Unlike a reporter containing *colEI*-derived LexA-binding sites, one derived from *sula* has no apparent leak in the adult or larval CNS when assayed by histochemical methods.

The DNA-binding and transcription-activating functions of GAL4 are accomplished through different functional domains of the protein that can be separated into distinct polypeptides (BRENT and PTASHNE 1985; KEEGAN *et al.* 1986). When association of the separated domains is promoted by protein–protein interactions, the activity of GAL4 as a transcription factor is restored; this is the basis of the two-hybrid method for screening for protein–protein interactions (FIELDS and SONG 1989). LUAN *et al.* (2006) demonstrated that it is possible to drive GAL4's DNA-binding and activation domains separately, under different enhancers, thereby restricting reporter expression to the overlap of the two patterns, where the complete GAL4 is reconstituted by means of a leucine zipper attached to each domain (Split GAL4). However, the expression levels obtained with Split GAL4 were greatly reduced from those obtained with the same enhancers driving intact GAL4, even when the strong VP16 activation domain was used. We improved the efficacy of this method, primarily by the use of the p65 activation domain.

Another strategy for refining expression patterns in GAL4 lines is targeted suppression of GAL4 activity in a subset of cells comprising the pattern by expression of GAL80 (LEE and LUO 1999); GAL80 binds to GAL4 and neutralizes its transcription-promoting activity (YUN *et al.* 1991; TRAVEN *et al.* 2006). The successful implementation of this strategy requires that GAL80 be expressed at a sufficiently high level (JOHNSTON and HOPPER 1982; SALMERON *et al.* 1989). We wanted to be able to use GAL80 to suppress GAL4-driven transcription when GAL4 and GAL80 are driven by enhancers of similar strength. To this end, we generated and tested vectors expressing a version of a GAL80 optimized for *Drosophila* codon usage and varied both the copy number and the presence of two post-transcriptional regulatory elements: an intron and the woodchuck post-transcriptional regulatory element (WPRE). The WPRE has been shown to increase protein expression from

viral vectors in mammalian cells (ZUFFEREY *et al.* 1999). We also tested mutant versions of GAL80 that were reported to provide greater suppression of GAL4 activity in yeast.

The ability to repeatedly target the same genomic sites using PhiC31 integrase (GROTH *et al.* 2004) is a major advance in that it enables the experimenter to control for the influence of local genomic environment on transgene expression (LEWIS 1950; WILSON *et al.* 1990). However, the many locations where the *attP* docking site has been inserted vary themselves in their local environments, and it is necessary to test each site for each desired property. We assayed 16 genomic *attP* docking sites to identify sites that showed minimal expression in the adult nervous system when a basal enhancer trap vector was inserted, allowed an exogenous enhancer to drive strong expression, and allowed a UAS construct to respond strongly to the presence of GAL4. Further, by using site-specific integration of transgenes (GROTH *et al.* 2004), we were able to directly compare constructs without the variation that results from insertion at different genomic locations (SPRADLING and RUBIN 1983).

Taken together, the efforts described in this article have generated and characterized a new set of vectors and methods that allow unprecedented control over the expression of exogenous genes in *Drosophila*. These vectors are modular to facilitate further improvements and allow the addition of enhancer fragments in a reproducible orientation by site-specific recombination using Gateway technology (Invitrogen, Carlsbad, CA). When integrated into well-characterized genomic locations, this approach maximizes the consistency and predictability of the resultant expression patterns.

MATERIALS AND METHODS

Codon optimization and gene synthesis: Codon optimization was performed using Gene Designer (VILLALOBOS *et al.* 2006; DNA 2.0). DNA 2.0 (Menlo Park, CA) synthesized the DNA.

Construction of GAL4, LexA, Split GAL4, and GAL80 vectors: Standard molecular biology methods were used and constructs were sequence verified prior to injection into flies. Restriction enzymes and mung bean nuclease were from New England Biolabs (Ipswich, MA). PCR amplifications were performed with *PfuUltra* High-Fidelity DNA polymerase (Stratagene, La Jolla, CA). Vectors, maps, and sequences are available from Addgene (<http://www.addgene.org/pgvec1>).

Construction of GAL4 vectors: Synthesized *Drosophila* codon-optimized GAL4 was cloned into pBPGUw (PFEIFFER *et al.* 2008) either as a 5'-*KpnI* to 3'-*HindIII* or a *HindIII* fragment to include the indicated UTR and terminator. The yeast transcriptional terminator was derived from pBPGUw. The SV40 transcriptional terminator was PCR amplified from Janelia Farm Reporter Construct (JFRC) pJFRC-MUH (see below) and cloned 5'-*HindIII* to 3'-*SpeI*, replacing the *hsp70* terminator. GAL4 deletion variant II-9, which includes the published GAL4d (MA and PTASHNE 1987a) and the yeast transcriptional terminator, was excised from plasmid G610

(gift of Gary Struhl, Columbia University, New York) as a 5'-*KpnI* to 3'-*HindIII* fragment. A multistep cloning process was used to construct the codon-optimized GAL4d variant. First, the codon-optimized GAL4 DNA-binding domain (DBD) (amino acids 1–147) and the activation domain II (ADII) (amino acids 768–881) were PCR amplified from a codon-optimized GAL4 gene. Second, the PCR amplicons were cloned as a triple ligation into pBDP (PFEIFFER *et al.* 2008) 5'-*EcoRI* to 3'-*NotI*. The resultant vector, pBDP236, includes a *BamHI* linker between the GAL4 DBD and ADII protein domains. Finally, the codon-optimized GAL4d was excised from pBDP236 as a 5'-*KpnI* to 3'-*HindIII* fragment and cloned into pBPGUw. Codon-optimized GAL4::p65 and GAL4::VP16 were made by first liberating GAL4 DBD from pBDP236, as a 5'-*KpnI* to 3'-*BamHI* fragment, and then cloning it as a fusion to codon-optimized p65 (amino acids 283–551) or VP16 (amino acids 413–490) activation domains. GAL4::p65 was cloned 5'-*KpnI* to 3'-*PmeI* into pBPLexA::p65Uw from which LexA::p65 had been removed. GAL4::VP16 was cloned by excising GAL4::p65 from pBPGAL4.2::p65Uw as a *HindIII* fragment and replacing it with GAL4::VP16.

Construction of LexA vectors: LexA::VP16 was PCR amplified from pBS_LexA::VP16_SV40 (LAI and LEE 2006) and cloned 5'-*KpnI* to 3'-*HindIII* into pBPGUw to create pBPLexA::VP16Uw. Codon-optimized LexA transgenes were cloned in pBPGUw as described above. LexA vectors pBPnlsLexA::GADfUw and pBPnlsLexA::p65Uw contain an N-terminal nuclear localization signal consisting of 11 amino acids (residues 125–135) derived from SV40 large T antigen (SMITH *et al.* 1985).

Construction of Split GAL4 vectors: Design of the Split GAL4 vectors has been described (LUAN *et al.* 2006). However, we included codon-optimized GAL4 DNA-binding domain and p65 activation domain and corrected the Y → N mutation at amino acid 36 of the leucine zipper domain in the VP16AD and GAL4AD versions of LUAN *et al.* (2006) to create pBPZpGAL4DBDUw and pBPp65ADZpUw.

Construction of GAL80 vectors: Codon-optimized GAL80 was cloned 5'-*KpnI* to 3'-*HindIII* into pBPGUw and pBPGAL4.2Uw-2 to create pBPGAL80Uw-1 and pBPGAL80Uw-5. The Drosophila *Myosin heavy chain* intron 16 was PCR amplified from pJFRC2 (see below) and cloned 5'-*KpnI* to 3'-*NheI* in pBPGAL80Uw-1, making pBPGAL80Uw-3. The WPRE was PCR amplified from FLEX vector DNA (ATASOY *et al.* 2008) with flanking *HindIII* sites and cloned into pBPGAL80Uw-1 and pBPGAL80Uw-3 to generate pBPGAL80Uw-2 and pBPGAL80Uw-4, respectively. pBPGAL80Uw-6 was generated in the same fashion as pBPGAL80Uw-4, but using pBPGAL80Uw-5 instead of pBPGAL80Uw-1 as the starting vector.

Construction of pJFRC reporter vectors: pJFRC-MUH was created in a multistep cloning process. First, pBDP (PFEIFFER *et al.* 2008) was cut with *BglII*, treated with DNA polymerase, and religated. Next, two copies of 5XUAS sites were PCR amplified from pUASBP (HORNE-BADOVINAC and BILDER 2008) as 5'-*NotI/HindIII* to 3'-*AvrII* and 5'-*AvrII* to 3'-*NheI/BamHI* and cloned, as a triple ligation, 5'-*NotI* to 3'-*BamHI* into pBDP. The resultant plasmid, pBDP-10XUAS, was digested 5'-*NheI* to 3'-*BamHI* and ligated with a PCR-amplified *hsp70* basal promoter that included flanking 5'-*AatII* and 3'-*BglII* sites from pUASBP, generating pBDP-MUH. Mung bean nuclease was used to destroy the *NotI* site in pBDP-MUH. Finally, the SV40 terminator and multiple cloning site (MCS) were extracted from pUASBP as a *BglII* to *FseI* fragment and cloned into pBDP-MUH, yielding pJFRC-MUH.

Construction of vectors pJRC1–pJFRC8: mCD8::GFP was removed from pUAST (LEE and LUO 1999) as a *XhoI* to *XbaI* fragment and then cloned into pJFRC-MUH to make pJFRC1. To generate pJFRC2, the Drosophila *Myosin heavy chain* intron

16 was PCR amplified to include splice site consensus sequences using Phusion High-Fidelity polymerase (FINNZYMES, Espoo, Finland) from *y; cn bw sp* DNA (ADAMS *et al.* 2000) and cloned as a 5'-*BglII* to 3'-*NotI* fragment into pJFRC1. Promoters containing an *hsp70* basal promoter and one or three UAS sites were cloned into pJFRC2 5'-*HindIII* to 3'-*BglII* to yield pJFRC3 and pJFRC4, respectively. Digestion of pJFRC2 with *AvrII* and *NheI* and subsequent ligation with the *hsp70* promoter and intron removed 5 copies of the UAS site, generating pJFRC5. A modular cassette containing 10 additional UAS copies was cloned in pJFRC2 as a 5'-*AatII* to 3'-*NheI* fragment, yielding pJFRC7, followed by a subsequent digest with *NheI* and *SpeI* to yield pJFRC6. pJFRC8 was made by cutting pJFRC7 with *HindIII*, blunting with DNA polymerase, digesting with *ZraI*, and finally cloning as a blunt end 20XUAS fragment into *ZraI*-cut pJFRC7.

Construction of pJRC9–pJFRC11 tandem vectors: To construct pJFRC9, pJFRC2 was first cut with *HindIII* and made blunt using DNA polymerase, followed by *PmeI* digestion and gel extraction. The resultant fragment was cloned into pJFRC2, which was cut with *FseI* and treated with DNA polymerase; products were screened for orientation. pJFRC10 and pJFRC11 were created in a multistep process. First, pJFRC2 was cut with *FseI*, followed by ligation with a synthesized gypsy-insulated spacer of 2.8 kb, generating pJFRC2-INS. pJFRC2-INS was cut with *PmeI* and ligated with a *HindIII* (blunt) to *PmeI*-cut pJFRC2 fragment (see above). Orientation was determined via PCR and restriction digest.

Construction of pJFRC12–pJFRC14: DNA encoding the first 85 amino acids of Drosophila *Src oncogene at 64B* (*Src64B*) was PCR amplified from P{UAS-myr-mRFP} (gift of Henry Chang, Purdue University, West Lafayette, IN) as a 5'-*XhoI* to 3'-*BamHI* fragment and cloned into pJFRC2, replacing the mCD8 membrane tag. Next, a Drosophila codon-optimized GFP utilizing the same F64L and S65T mutations as in the published version (LEE and LUO 1999) was cloned 5'-*BamHI* to 3'-*XbaI*, creating pJFRC12. Codon-optimized GFP from pJFRC12 was generated by PCR amplification and used to replace the myr::GFP transgene in pJFRC12 as a 5'-*XhoI* to 3'-*XbaI* fragment, making pJFRC13. Next, the WPRE was PCR amplified from FLEX vector DNA and cloned as a *XbaI* fragment into pJFRC13, yielding pJFRC14.

Construction of pJRC15–pJFRC18: A modular cassette, containing eight LexA-binding sites from the *sulA* operator and an *hsp70* basal promoter, was cloned in pJFRC1 as a 5'-*HindIII* to 3'-*BglII* fragment yielding pJFRC18. Five LexA-binding sites were PCR amplified from pJFRC18-8XLexAop2-mCD8::GFP with the inclusion of a 3'-*SpeI* restriction site. Next, the PCR amplicon was cloned 5'-*NheI* to 3'-*AatII* into pJFRC18 to generate pJFRC15. pJFRC16 was made as follows: pJFRC18 vector was digested with *HindIII* and *ZraI* to liberate a fragment containing eight LexA-binding sites; the fragment was gel extracted and the *HindIII* sticky ends were filled in; the *HindIII* (blunt) to *ZraI* fragment was cloned into an *AvrII*-cut 8XLexAop2-mCD8::GFP that was made blunt with DNA polymerase, creating pJFRC16. pJFRC17 was generated in a similar fashion, but using pJFRC15 as template DNA for all steps.

Adult brain dissection and histochemistry: Flies for imaging GFP expression were bred from homozygous driver females crossed to homozygous reporter males. Brains of adult female flies were dissected in cold PBS and fixed in 0.8% paraformaldehyde (Electron Microscopy Science, Hatfield, PA) in PBS at 4° overnight. After four 30-min washes in 0.5% BSA and 0.5% Triton X-100 in PBS (PAT), samples were blocked with 3% normal goat serum (NGS) in PAT for 2 hr at room temperature. Samples were then incubated overnight at 4° in a primary antibody solution containing mouse anti-nc82 (1:50;




FIGURE 1.—Diagram of pBP cloning vectors for GAL4, LexA, GAL80, and Split GAL4. All constructs contain the pUC19-derived bacterial origin of replication and ampicillin resistance gene, the PhiC31 *attB* site, the mini-white

marker for identification of transformants in *Drosophila*, and the DSCP basal promoter (PFEIFFER *et al.* 2008). The vector backbone is modular to allow for many possible combinations: gray shading indicates components that were held constant, while the colored elements were varied between the constructs we describe in this report. Abbreviations: CRM, conserved regulatory module (generally a 2- to 3-kb enhancer-containing fragment of *Drosophila* DNA); IVS, intervening sequence within the 5'-UTR; WPRE, a woodchuck hepatitis virus post-transcriptional regulatory element; and TERMINATOR, the transcriptional terminator.

Developmental Studies Hybridoma Bank, Iowa City, IA), rabbit anti-GFP IgG (1:1000; no. A11122, Invitrogen), and 3% NGS in PAT. After four 30-min washes in PAT, samples were incubated overnight at 4° in a secondary antibody solution containing Alexa Fluor 568 goat anti-mouse IgG (1:1000, Invitrogen), Alexa Fluor 488 goat anti-rabbit IgG (1:1000, Invitrogen), and 3% NGS in PAT. After at least four 30-min washes in PAT, samples were rinsed in PBS and mounted in Vectashield mounting medium (Vector Labs, Burlingame, CA) within multiwell silicone adhesive spacers (Grace Bio-labs, Bend, OR). Samples were covered with a no. 1.5 glass coverslip before imaging.

Immunolabeled adult brains were imaged with a Model 510 laser scanning confocal microscope (Zeiss, Thornwood, NY) under 20× magnification. Twelve-bit z-stack images were scanned at 1- μ m section intervals with a resolution of 1024 × 1024 pixels. Z-projection images were converted from 12-bit to 8-bit, inverted, and rotated using macros written for Fiji (http://pacific.mpi-cbg.de/wiki/index.php/Main_Page). Image processing macros are available upon request.

Larval dissection and histochemistry: Larval tissues were dissected in PBS and fixed for 1–2 hr in 4% paraformaldehyde at room temperature. After multiple rinses in PBS with 1% Triton X-100 (PBS-TX), tissues were preblocked in 2% NGS in PBS-TX for 30 min and then incubated overnight at 4° with mouse anti-neuroglian (1:50 BP-104; Developmental Studies Hybridoma Bank) and rabbit anti-GFP IgG (1:1000) in PBS-TX. After multiple rinses in PBS-TX, tissues were incubated overnight in the cocktail of fluorescent secondary antibodies described above. Nervous systems were then washed two to three times in PBS-TX, mounted on polylysine (Sigma, St. Louis)-coated coverslips, dehydrated through a graded ethanol series, cleared in xylene, and mounted in DPX Mountant (Sigma).

Immunolabeled larval nervous systems were imaged under 40× magnification as a 2 × 3 array of tiled stacks. Each stack was scanned as an 8-bit image with a resolution of 512 × 512 and a z-step interval of 2 μ m. For a given series, all images were taken at the same gain settings.

Quantitative reverse transcriptase PCR: Flies were anesthetized with CO₂ and then frozen on dry ice. Heads were removed with a scalpel and immediately placed in Eppendorf tubes containing TRIzol reagent (Invitrogen) on ice. Heads were homogenized in TRIzol using a pellet pestle (Kontes, Vineland, NJ) and RNA was extracted according to Invitrogen instructions. RNA concentration was read using a NanoDrop ND-1000 spectrophotometer (Nano Drop Technologies, Wilmington, DE). RNA integrity was confirmed on a nondenaturing agarose gel. Reverse transcription was performed on 1 μ g of RNA treated with gDNA Wipeout Buffer using the QuantiTect Reverse Transcription kit (QIAGEN, Valencia, CA) in a final volume of 20 μ l. PCR was carried out using 2.5 μ l of the reverse transcription reaction and 15 μ l of Brilliant SYBR Green QPCR Master Mix (Stratagene) in a total volume of 30 μ l. Cycling conditions were as follows: 95° for 10 min followed by 40 cycles at 95° for 30 sec, 55° for 1 min, and 72° for 30 sec.

QRT-PCR reactions were run in the Stratagene Mx3005P and analyzed with the accompanying MxPro software. Experiments included no-reverse-transcriptase controls for each template and no-template controls for each pair of primers. Percentage of error was determined by dividing the upper and lower relative quantity (RQ) value limits by the reported value and multiplying by 100. The given error is the largest resultant percentage of error from all samples. Primers used were as follows: GFP, CM29F 5'-ATTGGCGATGGCCCTGTCCT-3' and CM30R 5'-GTTTCATCCATGCCATGTGTAATCC-3'; and *Drosophila melanogaster beta-Tubulin at 56D* (NM_079071) (normalizer), CM57F 5'-ATCCCGCCCCGTGGTCTG-3' and CM59R 5'-AAAGCCTTGCGCCTGAACATAGC-3'.

***Drosophila* stocks:** Flies were reared at 25° and raised on standard cornmeal/molasses food. In addition to the materials presented in this study we used three published transgenic flies: *y w; UAS-mCD8::GFP*; + and *y w; Pin/CyO; UAS-mCD8::GFP* (LEE and LUO 1999) and *w; Sp/CyO; LexAop-rCD2::GFP* (LAI and LEE 2006).

RESULTS

Optimization of vectors for GAL4 expression: We examined the effects of altering the sequence of the GAL4 gene and the UTR sequences that flank it in commonly used vectors. Figure 1 diagrams the structure of the vector we used to test these variants and Table 1 lists the resultant constructs. Codon-optimizing genes for expression in heterologous hosts can improve levels of protein expression (GUSTAFSSON *et al.* 2004). We found that using a variant of the yeast GAL4 gene that had been optimized for both *Drosophila* codon-usage and translation-initiation sequence increased levels of GAL4-driven GFP by ~50% (compare Figure 2B with 2C).

The GAL4 gene from pGaTB and pGawB (BRAND and PERRIMON 1993), present in most enhancer trap vectors, contains two additional DNA segments whose effects on the transcription of the GAL4 gene have not been systematically investigated: 45 bp of *hsp70* 5'-UTR and the yeast 3'-GAL4 transcriptional terminator (BRAND *et al.* 1994). It has been suggested that sequences within the cloned *hsp70* 5'-UTR of GAL4 might direct the larval salivary gland background expression common to most *P*-element-generated GAL4 insertions (GERLITZ *et al.* 2002; HRDLICKA *et al.* 2002). We found that removal of one or both of these elements modestly decreased the level of GAL4-driven transgene expression (compare Figure 2C with 2D, and data not shown). Moreover, our collection of GAL4 drivers contains these sequences, but

TABLE 1
New GAL4, LexA, Split GAL4, and GAL80 vector backbones used in this study

| Name | 5'-UTR IVS | Transgene | 3'-UTR WPRE | Terminator |
|---------------------|------------|------------------------------------------------|-------------|--------------|
| pBPGAL4.1Uw | | GAL4 ^a | | <i>hsp70</i> |
| pBPGAL4.2Uw | | GAL4 ^a | | <i>hsp70</i> |
| pBPGAL4.2Uw-2 | | GAL4 ^a | | SV40 |
| pBPGAL4dUw | | GAL4 deletion variant II-9 (GADd) | | <i>hsp70</i> |
| pBPGAL4d.2Uw | | GAL4 deletion variant II-9 ^a (GADd) | | <i>hsp70</i> |
| pBPGAL4.2::VP16Uw | | GAL4::VP16 ^a | | <i>hsp70</i> |
| pBPGAL4.2::p65Uw | | GAL4::p65 ^a | | <i>hsp70</i> |
| pBPlexA::GADdUw | | LexA::GADd ^a | | <i>hsp70</i> |
| pBPlexA::GADflUw | | LexA::GADfl ^a | | <i>hsp70</i> |
| pBPnlsLexA::GADflUw | | nlsLexA::GADfl ^a | | <i>hsp70</i> |
| pBPlexA::VP16Uw | | LexA::VP16 | | <i>hsp70</i> |
| pBPlexA::p65Uw | | LexA::p65 ^a | | <i>hsp70</i> |
| pBPnlsLexA::p65Uw | | nlsLexA::p65 ^a | | <i>hsp70</i> |
| pBPZpGAL4DBDUw | | Zip-GAL4DBD ^a | | <i>hsp70</i> |
| pBPp65ADZpUw | | p65AD-Zip ^a | | <i>hsp70</i> |
| pBPGAL80Uw-1 | | GAL80 ^a | | <i>hsp70</i> |
| pBPGAL80Uw-2 | | GAL80 ^a | + | <i>hsp70</i> |
| pBPGAL80Uw-3 | + | GAL80 ^a | | <i>hsp70</i> |
| pBPGAL80Uw-4 | + | GAL80 ^a | + | <i>hsp70</i> |
| pBPGAL80Uw-5 | | GAL80 ^a | | SV40 |
| pBPGAL80Uw-6 | + | GAL80 ^a | + | SV40 |

BP plasmid vector backbones are derived from pBPGUw (PFEIFFER *et al.* 2008) and contain the pUC19-derived bacterial origin of replication and ampicillin resistance gene, the PhiC31 *attB* site, the mini-white marker for identification of transformants in *Drosophila*, and the DSCP basal promoter. For more details see Figure 1 and Addgene plasmid 17575. Abbreviations: U, DSCP basal promoter; w, mini-white marker; nls, nuclear localization signal; IVS, intervening sequence within the 5'-UTR; WPRE, a woodchuck hepatitis virus post-transcriptional regulatory element within the 3'-UTR; TERMINATOR, the transcriptional terminator; and pBP, plasmid BP backbone.

^a*Drosophila* codon-optimized transgene.


lacks the salivary gland background (PFEIFFER *et al.* 2008). If indeed the *P*-element vector carries a cryptic salivary gland enhancer, it seems to have been lost in our constructs.

Most GAL4 constructs carry the *hsp70* 3'-UTR, which contains degradation sequences that cause rapid turnover in non-heat-shock conditions (PETERSEN and LINDQUIST 1989). Replacing the *hsp70* transcriptional terminator used in our GAL4 vectors with the SV40 UTR is expected to result in greater mRNA stability, consistent with the increased expression levels we observed (Figure 2F). It may also result in perdurance of expression from earlier developmental stages, one explanation for the extra cells observed when using CRM R9C11-GAL4-SV40 (Figure 2F). Similar results were obtained using enhancers R9C11, R9B05, and R9D11 (supporting information, Figure S1, and PFEIFFER *et al.* 2008).

Choice of activation domain can strongly affect levels of transcription (PTASHNE 1988; MELCHER 2000). We compared the GFP expression patterns driven by GAL4 constructs with four different activation domains: (1) GAL4; (2) GAL4 deletion variant II-9 (GAL4d, GAL4 amino acid residues 1–147 fused by a small linker with 768–881; MA and PTASHNE 1987a), which has been used in LexA (LAI and LEE 2006) and Split GAL4 vectors (LUAN *et al.* 2006); (3) herpes simplex virus protein VP16

(SADOWSKI *et al.* 1988); and (4) human p65 (SCHMITZ and BAEUERLE 1991), which has been successfully used to drive transcription of reporter transgenes in *Drosophila* as part of GeneSwitch (OSTERWALDER *et al.* 2001; ROMAN *et al.* 2001). Figure 3 shows expression driven by these GAL4 variants. R9C11-GAL4d (Figure 3B) drove GFP at a greatly reduced level, relative to intact GAL4 (Figure 3A). Conversely, replacing the GAL4 activation domain with either VP16 (Figure 3C) or p65 (Figure 3D) resulted in severalfold increases in GFP mRNA; the observed expression patterns were also broader, presumably because weakly expressing cells became visible. Although GAL4::p65 yielded the highest transcription levels, it reduced transformant viability. Cytotoxicity has been previously reported when GAL4 is expressed at very high levels (KRAMER and STAVELEY 2003).


Improved UAS reporter constructs: Using a modular backbone (Figure 4), we generated a series of UAS-mCD8::GFP reporter constructs (Table 2) and used them to determine the effects on GFP expression of (1) the choice of basal promoter, (2) the presence of an intron in the 5'-UTR, (3) the number of UAS sites, (4) the copy number of the reporter construct, (5) the nature of the protein localization signals fused to the GFP protein, and (6) the presence of the WPRE regulatory element in the 3'-UTR.



SV40 terminator replacing the *hsp70* terminator. Relative quantities of GFP mRNA expression levels as measured by QRT-PCR in homogenates of heads of each genotype relative to the control (calibrator) in A, which was arbitrarily set at 1.0, are indicated in the top right of each panel. Assays were done in triplicate except for F, which was done in duplicate; error was within 9% of reported values.

We tested two basal promoters, the *Drosophila* synthetic core promoter (DSCP) (PFEIFFER *et al.* 2008) and the *hsp70* basal promoter (BRAND and PERRIMON 1993) to determine the levels of expression they gave when paired with UAS sites in the presence or absence of GAL4. The DSCP contains a large set of core promoter elements to promote robust expression with a broad range of enhancers that bind different activator proteins, which themselves might have specific preferences

for one or more of these promoter motifs (PFEIFFER *et al.* 2008). While the DSCP promoter works well with a variety of enhancers, we found that in the specific case of GAL4-driven UAS expression, the *hsp70* basal promoter yielded twofold higher expression levels than the same construct built with the DSCP, while still displaying nearly undetectable leak in the absence of GAL4 (data not shown). We therefore used the *hsp70* basal promoter in subsequent UAS constructs.



in C, but with the activation domain from p65. Relative GFP QRT-PCR values, standardized to *attP2* crossed to UAS-mCD8::GFP (set at 1.0), are indicated in the top right of each panel. Assays were done in triplicate; error was within 5% of reported values.

FIGURE 2.—Effects of codon optimization and terminators on GAL4-driven GFP transgene expression. Adult brains are shown after immunostaining to reveal GFP expression. (A) As a control for transcription of the UAS-mCD8::GFP reporter construct (LEE and LUO 1999) in the absence of a GAL4 driver, as well as for the background of the immunohistochemistry procedure, UAS-mCD8::GFP was crossed to the *attP2* site with no integrated construct. (B–F) The CRM R9C11 fragment (PFEIFFER *et al.* 2008) was used to drive GAL4 expression in constructs that are integrated into the *attP2* site and crossed to the UAS-mCD8::GFP reporter. (B) The GAL4 gene from BRAND *et al.* (1994), which contains 45 bp of the *hsp70* 5'-UTR and transcriptional terminators from both the GAL4 gene and the *hsp70* gene. CRM R9C11 drives expression prominently in the antennal mechanosensory and motor center (AMMC) and mushroom body (MB). (C) GAL4.1, the same construct as in B, but with a GAL4 coding sequence optimized for *Drosophila* codon usage. (D) GAL4.2, the same construct as in C, but with the 45-bp *hsp70* 5'-UTR and yeast transcriptional terminator removed. (E) Same as D, but with GAL4 deletion variant II-9 (pMA236; MA and PTASHNE 1987a) replacing the full-length GAL4 gene. (F) Same as D, but with the

FIGURE 3.—Activation domain choice has a large effect on GAL4-driven levels. *Drosophila* adult brains were immunostained for GFP after crossing drivers to the UAS-mCD8::GFP reporter, as in Figure 2. All GAL4 constructs are directed by CRM R9C11, integrated into *attP2*, and contain an *hsp70* terminator. (A) GAL4 from pGawB (BRAND and PERRIMON 1993). (B) GAL4d, containing the GAL4 deletion variant II-9 (pMA236; MA and PTASHNE 1987a). The 45-bp segment of *hsp70* 5'-UTR has been removed, but the yeast transcriptional terminator from the GAL4 gene is present. (C) GAL4.2::VP16, containing a fusion of the GAL4 DNA-binding domain to the VP16 activation domain. The entire coding region has been optimized for *Drosophila* codon usage and the *hsp70* 5'-UTR and yeast transcriptional terminator have been removed. (D) GAL4.2::p65, as




FIGURE 4.—Diagram of pJFRC reporter constructs. All constructs contain the pUC19-derived bacterial origin of replication and ampicillin resistance gene, the PhiC31 *attB* site, the mini-white marker for identification of transformants in *Drosophila*, an *hsp70* basal promoter, and an SV40 transcriptional terminator. The vector

backbone is modular to allow for many possible combinations: gray shading indicates components that were held constant, while the colored elements were varied between the constructs we describe in this report. Examples of some of these alternatives are listed below colored elements; see text for more details.

Intervening sequences (IVS, introns) placed in the 5'-UTR of genes can boost expression by promoting steady-state export of spliced mRNAs to the cytoplasm (HUANG and GORMAN 1990; DUNCKER *et al.* 1997; ZIELER and HUYNH 2002). We added a 67-bp intron from *Drosophila Myosin heavy chain* (Mhc IVS16) to pJFRC1, our 10XUAS-mCD8::GFP vector to make pJFRC2. GAL4-driven GFP mRNA levels from pJFRC2 were elevated 20% compared to the same construct without the intron (data not shown). We also tested four other introns: synthetic intron IVS8 (Invitrogen), *white* intron 2 (LEE and CARTHEW 2003), *ftz* intron (NI *et al.* 2009), and a hybrid intron (CHOI *et al.* 1991). As none were substantially better than Mhc IVS16 in terms of expres-

sion levels and background (data not shown), we chose to use Mhc IVS16 in subsequent constructs.

pJFRC2 contains 10 copies of an optimized GAL4 DNA-binding site, the “ScaI 17-mer” (WEBSTER *et al.* 1988), and drives GFP expression more than twofold higher than the UAS-mCD8::GFP construct described by LEE and LUO (1999) that contains 5 sites (compare Figure 5B with 5C). We varied the number of UAS sites from 5 to 40 and assayed levels of GFP expression driven from R9C11-GAL4 (Figure 5). Maximal GFP expression was obtained with 20 sites (pJFRC7; Figure 5E). Similar results were obtained by NI *et al.* (2008) with RNAi *Notch* hairpin-induced phenotypes.

Finally, while inclusion of gypsy insulators has been shown to boost transgene expression (MARKSTEIN *et al.*

TABLE 2

New reporter transgenes used in this study

| Name | Tandem construct | Operator | 5'-UTR IVS | Reporter | 3'-UTR WPRE |
|-----------|------------------|------------|------------|-----------------------|-------------|
| pJFRC-MUH | | 10XUAS | | | |
| pJFRC1 | | 10XUAS | | mCD8::GFP | |
| pJFRC2 | | 10XUAS | + | mCD8::GFP | |
| pJFRC3 | | 1XUAS | + | mCD8::GFP | |
| pJFRC4 | | 3XUAS | + | mCD8::GFP | |
| pJFRC5 | | 5XUAS | + | mCD8::GFP | |
| pJFRC6 | | 15XUAS | + | mCD8::GFP | |
| pJFRC7 | | 20XUAS | + | mCD8::GFP | |
| pJFRC8 | | 40XUAS | + | mCD8::GFP | |
| pJFRC9 | TH1 | 10XUAS | + | mCD8::GFP | |
| | | 10XUAS | + | mCD8::GFP | |
| pJFRC10 | THS2 | 10XUAS | + | mCD8::GFP | |
| | | 10XUAS | + | mCD8::GFP | |
| pJFRC11 | TTS3 | 10XUAS | + | mCD8::GFP | |
| | | 10XUAS | + | mCD8::GFP | |
| pJFRC12 | | 10XUAS | + | myr::GFP ^a | |
| pJFRC13 | | 10XUAS | + | GFP ^a | |
| pJFRC14 | | 10XUAS | + | GFP ^a | + |
| pJFRC15 | | 13XLexAop2 | | mCD8::GFP | |
| pJFRC16 | | 16XLexAop2 | | mCD8::GFP | |
| pJFRC17 | | 26XLexAop2 | | mCD8::GFP | |
| pJFRC18 | | 8XLexAop2 | | mCD8::GFP | |

Janelia Farm Reporter Construct (JFRC) backbones are derived from pBDP (PFEIFFER *et al.* 2008) and contain the pUC19-derived bacterial origin of replication and ampicillin resistance gene, the PhiC31 *attB* site, and the mini-white marker for identification of transformants in *Drosophila*. For more details see Figure 4 and Addgene plasmid 17566. In addition, all vectors also contain a basal promoter derived from *hsp70* and an SV40 transcriptional terminator (BRAND and PERRIMON 1993). Abbreviations: IVS, intervening sequence within the 5'-UTR; and WPRE, a woodchuck hepatitis virus post-transcriptional regulatory element within the 3'-UTR.

^a *Drosophila* codon-optimized GFP.




FIGURE 5.—Increasing the number of GAL4 DNA-binding sites boosts GFP levels. *Drosophila* adult brains were immunostained for GFP after crossing R9C11-GAL4 to mCD8::GFP reporters with 5 to 40 UAS sites. With the exception of the UAS-mCD8::GFP construct of LEE and LUO (1999), which is a *P*-element insertion on the second chromosome, all constructs are integrated into *attP2*. (A) *attP2* (no GAL4 driver) crossed to pJFRC2 (negative control). (B–F) R9C11-GAL4 crossed to reporters containing (B) 5, (C) 10, (D) 15, (E) 20, and (F) 40 UAS sites. We also tested a 5XUAS construct in the pJFRC backbone (pJFRC5; see Table 2), which gave similar results to UAS-mCD8::GFP (data not shown). Relative GFP QRT-PCR values, normalized to a level of 1.0 for *attP2* × UAS-mCD8::GFP (see Figure 2A), are indicated in the top right of each panel. Assays were done in triplicate; error was within 7% of reported values.

2008), we did not observe notable increases from the inclusion of these elements in pJFRC2 or pJFRC12 when integrated in *attP2* (data not shown).


We also tested expression driven from tandem constructs, containing two copies of pJFRC2 in a single insert (Figure 6; Table 2), as the ability to drive multiple UAS constructs without complicated genetics can be helpful. A tandem construct with two copies of the internal components of pJFRC2 in a tail-to-head orientation, pJFRC9 (Figure 6D), gave more expression than pJFRC2 (Figure 6B), but less than pJFRC7 (Figure 6C), which has the same number of UAS sites upstream of a single GFP gene. The addition of a 2.8-kb gypsy insulated spacer between the tandem copies of these same components in pJFRC10 (Figure 6E) increased expression to above that of pJFRC7. The relative orientation of the tandem genes was significant; a tail-to-tail construct with a spacer, pJFRC11 (Figure 6F), gave the highest level of GFP expression. Both the spacer and a tail-to-tail orientation appear to be required to obtain the expected twofold increase over pJFRC2. While helpful in increasing expression levels, such tandem constructs will likely have their greatest utility when used to direct the expression of two different responder genes under the control of the same GAL4 driver.

For many experiments, it is desirable to generate the same level of reporter expression while utilizing enhancers of very different strengths. For example, decreasing the number of UAS sites when using a strong enhancer-GAL4 driver will result in lower levels of reporter expression. We sought to evaluate our ability to modulate expression levels by varying the strength of the activation domain of the GAL4 driver and the

number of UAS sites carried by the reporter construct (Figure 7). mCD8::GFP driven from a single UAS site was almost undetectable, even with our strongest GAL4 driver, GAL4::p65 (Figure 7C). The expression levels obtained increased with UAS number from 3 to 20 and with activation domain strength (Figure 7, D–R). Thus, using a single enhancer, we can obtain a range of expression levels from undetectable to undesirably high and cytotoxic, by simply modulating the strength of the activation domain and UAS responder. The toxicity apparent with the GAL4::p65 driver and reporter constructs with ≥ 10 UAS sites (Figure 7, L, O, and R) appears to result largely from reporter protein expression levels, as this same driver with a 3X or a 5XUAS reporter results in labeled cells of apparently normal morphology (Figure 7, F and I; also see Figure S2).

Depending on the experiment, it may be desirable to target the reporter protein to either membrane or cytoplasmic sites. pJFRC2 employs the first 222 amino acids of the mouse CD8 protein to target GFP to the plasma membrane as first described by LEE and LUO (1999). We also evaluated a second method of targeting proteins to the membrane, *N*-myristoylation (RESH 1999); pJFRC12 employs the first 85 amino acids encoded by the *Drosophila Src oncogene at 64B*, Src64B, which has been used previously in *Drosophila* to target proteins to the membrane (MAUSS *et al.* 2009). Myristoylation improved signal strength; with 10XUAS, the *N*-myristoylated GFP reporter (pJFRC12; Figure 7, M–O) expresses GFP at levels similar to our 20× UAS-mCD8::GFP reporter (pJFRC7; Figure 7, P–R).

Signal strength observed with our cytoplasmic GFP reporter (pJFRC13; Figure 7, S–U) was weak compared



QRT-PCR values, standardized to $attP2 \times UAS-mCD8::GFP$, are indicated in the top right corners. Assays were done in duplicate; error was within 13% of reported values.

to that obtained with an equivalent membrane-targeted GFP construct (pJFRC2; Figure 7, J–L). However, inclusion of the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (ZUFFEREY *et al.* 1999) in the 3'-UTR (pJFRC14; Figure 7, V–X) substantially increased GFP levels, making them comparable to those seen with pJFRC2. However, the addition of the WPRE did not cause a notable increase in GFP expression from either the myristoylated or the mCD8 membrane-targeted reporters (data not shown).

Improved LexA drivers and operators: LAI and LEE (2006) showed that a C-terminal fusion with either the GAL4 activation domain II (GADD, residues 768–881 of GAL4) or the more potent VP16 activation domain from herpes simplex virus allows LexA-driven transcription of reporter transgenes in a GAL80-sensitive or -insensitive manner, respectively. We sought to improve the potency of these published LexA drivers by fusing LexA with two alternative activation domains. First, we used an extended version of the GAL4 activation domain, GADfl (residues 148–881 of GAL4), which includes activation domains I and II (MA and PTASHNE 1987a). Second, we replaced VP16 with the human p65 activation domain. Also, because LexA is a prokaryotic protein and is not specifically targeted to the nucleus in eukaryotic cells (BRENT and PTASHNE 1984), we reasoned that a nuclear localization signal (NLS) might increase its ability to promote transcription.

We constructed R9C11 enhancer-directed LexA drivers with a codon-optimized GADD, VP16 (codon optimiza-

tion of VP16 did not significantly improve LexA-driven transgene expression; data not shown), codon-optimized GADfl, or codon-optimized p65, with or without an NLS (Table 1). We compared the patterns and strength of expression observed when these constructs drove LexAop-rCD2::GFP (LAI and LEE 2006). LexA drivers containing GADfl (Figure 8D) or p65 (Figure 8G) activation domains drove GFP expression at higher levels than GADD (Figure 8C) or VP16 (Figure 8F). In all cases, we observed the expected expression pattern, based on R9C11-GAL4 driving mCD8::GFP (Figure 8B). Surprisingly, expression levels of GFP driven from LexA::GADfl were only slightly lower than those obtained with LexA::p65. Although a rigorous quantitative comparison cannot be made, as the GFP reporter constructs used differ in structure and genomic location, the level of LexAop-rCD2::GFP expression driven from LexA::GADfl seemed comparable to that seen with R9C11-GAL4 driving the mCD8::GFP reporter of LEE and LUO (1999). Further, as expected, tub-GAL80 (LEE and LUO 1999) was able to suppress GFP expression from LexA::GADfl (data not shown). Addition of a nuclear localization signal to the LexA::GADfl (Figure 8E) or the LexA::p65 (Figure 8H) proteins modestly increased their efficacy.

LexA protein binds, with various affinities, to a 20-bp motif found in the promoters of >20 *E. coli* genes (SCHNARR *et al.* 1991; WADE *et al.* 2005). *Drosophila* LexA reporters (LAI and LEE 2006) have used the *colE1*-binding motif because it was found to have one of the

FIGURE 6.—Tandem reporters can be used to increase output. (A) Diagram of reporter constructs. Note variation in UAS copy number (indicated in the blue box), tandem orientation (indicated by the arrows), and presence of a gypsy-insulated spacer of 2.8 kb (INS). The synthesized spacer was designed by independently randomizing a minimum of five times (Shuffle program GCG Version 11.1; Accelrys, San Diego) a sequence derived from kanamycin CDS (base pairs 1–810) and a sequence derived from the *E. coli* lacZ CDS (base pairs 799–2000) and then fusing these randomized sequences. The spacer was then flanked on either end with 424 bp from the 5'-UTR of gypsy (base pairs 647–1074) that contains 12 binding sites for the *su(Hw)* protein (MARLOR *et al.* 1986; SPANA *et al.* 1988). (B–F) *Drosophila* adult brains immunostained for GFP after crossing R9C11-GAL4 driver to indicated reporter. All constructs integrated into *attP2*. (B and C) Controls showing driver pattern with (B) 10 UAS copies (pJFRC2) or (C) 20 copies (pJFRC7). (D) A tandem 10XUAS-mCD8::GFP reporter in a tail-to-head orientation (pJFRC9). (E) As in D, but with inclusion of a gypsy-insulated 2.8-kb spacer between inserts (pJFRC10). (F) As in E, but reporters are inserted tail to tail (pJFRC11). Relative GFP




FIGURE 7.—Tuning expression levels by varying the strength of the activation domain and UAS responder. *Drosophila* adult brains were immunostained for GFP. With the exception of the 5× UAS-mCD8::GFP (LEE and LUO 1999) construct all transgenes are integrated into *attP2*. CRM R9B05 was used to drive three GAL4 variants: standard GAL4 (as used in the constructs described by PFEIFFER *et al.* 2008), GAL4.2::VP16, or GAL4.2::p65. These three GAL4 drivers were crossed to different responders as indicated, which vary in number of UAS sites, localization tag, and inclusion of a WPRE: (A–C) The 1XUAS-mCD8::GFP (pJFRC3). (D–F) The 3XUAS-mCD8::GFP (pJFRC4). (G–I) The 5XUAS-mCD8::GFP of LEE and LUO (1999). (J–L) The 10XUAS-




FIGURE 8.—Improved LexA drivers with GADfl and p65 activation domains. *Drosophila* adult brains were immunostained for GFP after crossing LexA drivers to a published LexAop-rCD2::GFP (LAI and LEE 2006). All GAL4 and LexA constructs are directed by CRM R9C11 and integrated into *attP2*. (A) *attP2* (no LexA driver) crossed to published LexAop-rCD2::GFP (negative control; note “leak” expression in the lamina). (B) R9C11-GAL4 with UAS-mCD8::GFP. (C and D) R9C11-LexA drivers containing GAL4 activation domain variants GADd (C) or GADfl (D), crossed to rCD2::GFP. (E) As in D, but with a nuclear localization signal (nls). (F and G) R9C11-LexA drivers with GAL80-insensitive activation domains VP16 (F) or p65 (G), crossed to rCD2::GFP. (H) As in G, but with an nls. Relative GFP mRNA levels as measured by QRT-PCR, standardized to *attP2* × UAS-mCD8::GFP (set as 1.0), are indicated in the top right of each panel. Assays were done in duplicate; error was within 14% of reported values.

highest affinities for LexA (EBINA *et al.* 1983). Although the *colE1* sequence permits robust transgene expression in *Drosophila*, these LexA reporters allow low levels of expression, or leak, in the absence of LexA, presumably due to affinity of endogenous transcription factors for the *colE1*-derived LexA-binding sites (Figure 9A and data not shown). In an attempt to identify other LexA-binding sites that would support strong expression in the presence of LexA, but not show any expression in its absence, we compared leak and levels of GFP induction from reporter transgenes containing sites from *colE1* (EBINA *et al.* 1983), *sulA* (COLE 1983), *umuDC* (KITAGAWA *et al.* 1985; PERRY *et al.* 1985), or a synthetic 22-bp *lexA* operator (BRENT and PTASHNE 1984). The latter two operator sequences did not perform well in our assays and were dropped from further studies (data not shown). Moreover, the published *colE1* LexA-binding sites showed strong leak in both larval and adult brains when used to drive mCD8-GFP under the DSCP promoter in *attP2* (data not shown). Thus, we focused on *sulA*-derived LexA-binding sites for subsequent constructs. We also varied the number of binding sites, which we expected would influence levels of transgene expression on the basis of studies with the GAL4/UAS system (this study; NI *et al.* 2008). We built mCD8::GFP reporters containing 8, 13, 16, or 26 LexA DNA-binding sites from the *sulA* operator and found the 13× version to give optimal expression with minimal leak (Figure 9 and data not shown). This reporter (pJFRC15) reproduced the ex-

pected expression pattern for three different enhancer-LexA constructs (Figure 9).

Refinement of expression patterns using Split GAL4: LUAN *et al.* (2006) used GADd and VP16 as activation domains in their implementation of the Split GAL4 system. However, the low levels of reconstituted GAL4 expression obtained limit the utility of this intersectional approach. We tested whether the GADfl and p65 activation domains, which we have shown drive much higher expression levels than the GADd and VP16 domains when fused to the LexA DNA-binding domain, could similarly improve expression in the Split GAL4 approach. We used enhancer R20B05 to drive either GADfl or p65 Split GAL4 activation domains. These were combined with the GAL4 DBD driven under either R35B08 or R50B06 and their ability to drive pJFRC2 was assayed. The p65 domain performed well. Both $R35B08^{Gal4DBD} \cap R20B05^{p65AD}$ and $R50B06^{Gal4DBD} \cap R20B05^{p65AD}$ resulted in robust and specific GFP expression in the predicted cells, where the expression patterns of the two parent enhancers overlapped; expression outside the overlap was not detected (Figure 10). In contrast, the GADfl domain performed poorly; neither $R35B08^{Gal4DBD} \cap R20B05^{GADfl}$ nor $R50B06^{Gal4DBD} \cap R20B05^{GADfl}$ yielded detectable GFP expression (data not shown).

LUAN *et al.* (2006) reported instances where Split GAL4 intersections showed expression in cells not observed in either parent pattern and we also observed this phenomenon, to varying extents, in many of the

mCD8::GFP (pJFRC2). (M–O) The 10XUAS-myr::GFP (pJFRC12): myristoylated, codon-optimized GFP. (P–R) The 20XUAS-mCD8::GFP (pJFRC7). (S–U) The 10XUAS-GFP (pJFRC13): untagged (cytoplasmic), codon-optimized GFP. (V–X) As in S–U, but containing a WPRE in the 3′-UTR. Note that strength of the activation domain and UAS number can drive undesirable levels of GFP and cause cytotoxicity. (P and R) Weakly expressing cells in the optic lobe become prominent, while those that expressed robust levels are gone (see Figure S2).




FIGURE 9.—A LexA operator containing 13 binding sites from *sula* provides robust and nonleaky expression. *Drosophila* adult brains were immunostained for GFP. With the exception of LexAop-rCD2::GFP (LAI and LEE 2006) all constructs are integrated into *attP2*. (A) *attP2* (no LexA driver) crossed to LexAop-rCD2::GFP (negative control; note “leak” expression in the lamina indicated by arrowheads). (B) *attP2* (no LexA driver) crossed to pJFRC15-13XLexAop2-mCD8::GFP (pJFRC15; negative control, no detectable leak), a LexAop reporter containing 13 LexA-binding sites derived from *sula*. (C) *attP2* (no GAL4 driver) crossed to pJFRC2 (negative control). (D–L) Enhancers driving LexA variants (indicated in the bottom right of each panel) crossed to the LexA reporter pJFRC15: (D, G, and J) R9D11-LexA; (E, H, and K) R9C11-LexA; (F, I, and L) R9B05-LexA. (M–O) GAL4 driven by the same three enhancers crossed to pJFRC2: (M) R9D11-GAL4, (N) R9C11-GAL4, and (O) R9B05-GAL4.

Split GAL4 intersections we examined in the adult brain (A. NERN, B. D. PFEIFFER and G. M. RUBIN, unpublished results). One possible explanation is that stronger activation domains were used in the Split GAL4 constructs than in the parent lines; we have shown that both the VP16 and the p65 activation domains drive broader transcription than the GAL4 activation domain (Figure 7). We therefore made additional attempts to develop Split GAL4 reagents, employing the GADfl domain. Since the GADfl peptide is approximately seven times

larger than GADd, GADfl may introduce steric hindrance or other deleterious protein–protein interactions. However, our attempts to address this problem by increasing the length of the polyglycine linker connecting the leucine zipper to the GADfl domain from 20, 40, or 80 residues were unsuccessful (data not shown). In summary, when using the p65 activation domain, the Split GAL4 intersectional method performs well in a majority of cases. However, it is important to verify the resultant expression pattern by direct assays.




FIGURE 10.—Refinement of GFP expression using Split GAL4. *Drosophila* third instar central nervous systems were immunostained for GFP. All constructs are integrated into *attP2*. (A) *attP2* (no GAL4 driver) crossed to pJFRC2-10XUAS-IVS-mCD8::GFP (negative control). (B and C) R20B05^{p65AD} or R35B08^{GAL4DBD} with pJFRC2 (negative control: no detectable leak). (D) R20B05-GAL4 crossed to pJFRC2 drives expression in immature neurons of the optic lobes and in all of the lineages of secondary neurons in the central brain and ventral nerve cord but none of the primary neurons that are born during embryogenesis. (E) R35B08 crossed to pJFRC2 drives expression in primary neurons of the central brain and ventral nerve cord, as well as eight secondary lineages in the central brain and secondary lineages 0, 8, and 7 in the thoracic neuromeres of the ventral nerve cord (for a description of lineages see TRUMAN *et al.* 2004). (F) Crossing Split GAL4 DNA-binding domain driven by R35B08 (R35B08^{GAL4DBD}; enhancer fragment R35B08 cloned in vector pBPZpGAL4DBDUw) with a stock of R20B05^{p65AD} (enhancer fragment R20B05 cloned in vector pBPp65ADZpUw); pJFRC2 (*attP40*; *attP2*) yields GFP expression restricted to the overlap between the two parent patterns. (G) R50B06 crossed to pJFRC2 drives expression in primary neurons of the brain and central nervous system, secondary lineage BAmv3 (for a description of brain lineages, see PEREANU and HARTENSTEIN 2006) in the central brain, and secondary lineages 9, 17, and 23 of the ventral nerve cord. (H) Crossing Split GAL4 DNA-binding domain driven by R50B06 (R50B06^{GAL4DBD}) with a stock of R20B05^{p65AD}; pJFRC2 (*attP40*; *attP2*) yields GFP expression restricted to the overlap between the two parent patterns. In both F and H, expression in primary neurons is eliminated, as predicted.

Subtraction of GAL4 expression by GAL80: One of the features of the modular system of enhancers and vectors we are generating (PFEIFFER *et al.* 2008 and this study) is that, once the pattern of expression produced by an enhancer has been established, we expect to be able to use that enhancer to drive another protein in the same pattern. This assumption is particularly important for experiments using GAL80 to refine the patterns of GAL4-driven expression, as it has not been feasible to assay GAL80 expression directly. For the results to be predictable, the vectors used to express the two proteins must differ as little as possible in sequences that affect expression patterns. Moreover, GAL80 must be expressed at levels similar to or higher than GAL4, as it acts by directly binding to GAL4.

We first tested two enhancers that drive GAL4 in overlapping patterns and then moved one of the enhancers to a GAL80 vector. When these GAL4 and GAL80 constructs were present in the same fly, we obtained the expected pattern in which GAL4 activity is detected only in those cells that do not overlap between the patterns (Figure 11).

In the experiment described above the GAL80 vector used a 3'-UTR from Simian virus 40 (SV40), which had been used in previous GAL80 constructs (LEE and LUO 1999; STOLERU *et al.* 2004; SUSTER *et al.* 2004). However, after observing the strong effect on expression of including the SV40 UTR in GAL4 vectors (Figure 2 and also see Figure S1), we realized that it would be important




FIGURE 11.—Targeted refinement of a GAL4 pattern using GAL80. Dissected third instar central nervous systems were immunostained for GFP (green) and neurotactin (magenta). All GAL4 and GAL80 constructs are integrated in *attP2*; the reporter is a *P*-element insertion of UAS-mCD8::GFP on the second chromosome (LEE and LUO 1999). (A) R20B05 drives expression in the immature neurons of the optic lobes (OL) and in all of the lineages of secondary neurons in the central brain and ventral nerve cord in third instar larvae. (B) A single optical section of the region indicated by the blue line in A at the level of the intermediate commissures. R20B05 drives GFP expression in both anterior and posterior commissures of thoracic segments T1–T3 and abdominal segment A1: anterior commissures are indicated by solid yellow arrowheads. (C) As in B, but only the green channel (anti-GFP) is shown. (D) R15E07 drives expression in most of the secondary lineages in the central brain and VNC, with the

notable exception of the neuroblast lineages whose axon bundles comprise the anterior intermediate commissure in the thoracic segments. It does not drive optic lobe expression. (E) A single optical section of the region indicated by the blue line in D. Note that R15E07 drives GFP expression in only the posterior commissures; the anterior commissures lacking GFP expression are indicated by open yellow arrowheads. (F) As in E, but only the green channel (anti-GFP) is shown. (G) R15E07-GAL80-SV40 (*attP40*) crossed to *w*; UAS-mCD8::GFP; R20B05-GAL4. As predicted, GFP expression is now restricted to the optic lobes (OL), a few lineages in the central brain, and the thoracic and abdominal lineages that form the anterior intermediate commissure. (H) A single optical section of the region indicated by the blue line in G showing GFP expression restricted to the lineages of the anterior commissure: anterior commissures are indicated by solid yellow arrowheads. (I) As in H, but only the green channel (anti-GFP) is shown.

to use the same 3'-UTR in both our GAL4 and GAL80 vectors.

Thus, we generated a series of vectors for the expression of GAL80 that contain either the SV40 or the *hsp70* 3'-UTR (Table 1) and tested them with the enhancer R11F05 (Figure 12). R11F05 directs reporter expression to ~100 sensory neurons that project into the ventral nerve cord of the third instar larva. The constructs were integrated into two genomic docking sites: *attP2*, on the third chromosome, which shows robust expression with GAL4 drivers, and *attP40*, on the second chromosome, which supports weaker expression (see below). A single copy of R11F05-GAL80-SV40 in *attP2*, but not *attP40*, reduced GFP expression

generated by R11F05-GAL4 (in *attP2*) and UAS-mCD8::GFP (LEE and LUO 1999) to undetectable levels (Figure 12, B and C). The increased suppression seen when the GAL80 construct is inserted in *attP2* is presumably a simple reflection of the increased levels of transcription seen from constructs inserted at this genomic docking site compared with *attP40*. We also generated a tandem construct with two copies of R11F05-GAL80-SV40; when integrated in either *attP40* or *attP2*, this construct was able to suppress GFP expression to undetectable levels (data not shown).

When we substituted the *hsp70* UTR for the SV40 UTR in the GAL80 vector, suppression levels decreased (Figure 12, D and E). This decrease allowed us to test



FIGURE 12.—GAL80 suppression of GAL4 is improved with post-transcriptional regulatory elements (intron and WPRE). *Drosophila* third instar central nervous systems were immunostained for GFP. Enhancer R11F05 was used to drive different GAL80 constructs. These constructs were then tested against their parent enhancer using a recombinant reporter line of R11F05-GAL4 (*attP2*) and a *P*-element insertion of UAS-mCD8::GFP on the third chromosome. Both GAL4 and GAL80 constructs use an *hsp70* terminator, unless otherwise noted. GFP expression was assayed after crossing R11F05-GAL4 (*attP2*) UAS-mCD8::GFP to (A) *Canton S* (positive control), showing GFP expression in a subset of sensory neurons that project into the ventral nerve cord, and (B) R11F05-GAL80-SV40 (no post-transcriptional regulatory elements), integrated in *attP2*. The inset at the bottom right shows a portion of the VNC at higher gain. (C) As in B, but integrated in *attP40*. The inset at the bottom right shows a portion of the VNC at higher gain. (D) R11F05-GAL80, integrated into *attP2*. A small number of neurons in the pattern escape suppression (express GFP). (E) As in D, but integrated into the weaker site *attP40*. Note increased incidence of neurons that escape suppression. (F–I) Inclusion of post-transcriptional regulatory elements to R11F05-GAL80 increases the level of GFP suppression: (F) R11F05-GAL80 with a WPRE, in *attP40*; (G) R11F05-

GAL80 with an IVS, in *attP40*; (H) R11F05-GAL80 with both IVS and WPRE, in *attP40*; (I) R11F05-GAL80 with both IVS and WPRE, in *attP2*. Weak background GFP expression from GAL4-independent expression from the UAS-mCD8::GFP reporter was present in a small group of cells in all preparations (examples indicated by arrowheads).

other methods for raising levels of GAL80 expression. We explored the use of two post-transcriptional regulatory elements thought to act by increasing RNA transport from the nucleus to the cytoplasm, rather than mRNA stability: intron 16 (IVS) from *Drosophila Myosin heavy chain*, and the WPRE (ZUFFEREY *et al.* 1999). One

or both elements were added to R11F05-GAL80-*hsp70* (Table 1) and then assayed as above (Figure 12, F–I). Addition of either IVS or WPRE to R11F05-GAL80-*hsp70* increased the extent of GFP suppression. When both were added, a single copy of GAL80 was able to reduce GAL4-driven GFP expression to almost undetectable




FIGURE 13.—Map of evaluated genomic *attP* sites. The indicated 16 PhiC31 genomic *attP* integration sites were assayed for four properties: (1) expression in the adult nervous system when an enhancer trap vector was inserted, (2) expression from an exogenous enhancer, (3) expression from a UAS construct responding to a GAL4 driver, and (4) transgene integration rate. Sites shown

in red meet all four criteria, while those shown in blue performed well with UAS reporter constructs, but not with enhancer-GAL4 drivers. Sites shown in black were rejected. See text for details. Genomic *attP* site references: *attP1*, *attP2*, *attP3*, *attP18*, and *attP40* (GROTH *et al.* 2004; MARKSTEIN *et al.* 2008); *attP16* (MARKSTEIN *et al.* 2008); *VK00005*, *VK00016*, *VK00026*, and *VK00027* (VENKEN *et al.* 2006); and *su(Hw)attP1*, *su(Hw)attP2*, *su(Hw)attP4*, *su(Hw)attP5*, *su(Hw)attP6*, and *su(Hw)attP8* (Ni *et al.* 2009; this study).

levels when inserted in *attP40* and suppressed it completely when inserted in *attP2*. Thus, R11F05-IVS-GAL80-WPRE-*hsp70* suppresses GAL4 at least as well as the SV40 version. We expect the addition of IVS and WPRE would further enhance GAL4 suppression when added to a GAL80-SV40 construct, as might be required when using a weak enhancer to drive GAL80 expression; for this reason we constructed pBPGAL80Uw-6 (Table 1).

NOGI and FUKASAWA (1984) cloned and sequenced mutants of GAL80 (GAL80^o) that suppress GAL4 in both inducing and noninducing conditions in *S. cerevisiae*. One of these mutants, GAL80^{o-1}, contains a glycine-to-arginine substitution at amino acid 323, which is

thought to give it a higher affinity for GAL4 (SALMERON *et al.* 1990). We thought this mutation might also increase its GAL4 suppression in *Drosophila*, so we generated lines in which the R11F05 enhancer drives GAL80^{o-1} or a triple-mutant GAL80 containing the *S-0*, *S-1*, and *S-2* mutations, with or without the addition of IVS and WPRE. These GAL80^o constructs varied in their ability to suppress GAL4-driven GFP expression, but none was substantially better than 11F05-IVS-GAL80-WPRE-*hsp70* (data not shown).

Assaying position effects at genomic *attP* docking sites: To generate complex genotypes it will be necessary to have several *attP* sites with similar and favorable pro-




FIGURE 14.—Chromatin effects on R9C11-GAL4. *Drosophila* adult brains were immunostained for GFP. R9C11-GAL4 was integrated into 10 *attP* docking sites and crossed to pJFRC2 in *attP2*. The genomic docking site is shown in the top left corner of each panel and the chromosome arm of the insertion site in the top right. We were unable to get transformants in the *attP3* and *VK00026* sites. Four sites showed reproducible and robust expression, comparable to our standard *attP2* insertion: *attP18*, *su(Hw)attP8*, *attP40*, and *VK00027*. Genomic docking sites flanked with gypsy insulators [indicated by *su(Hw)* in the name] share a common background leak in a half-dozen cells in the lateral horn (see Figure S3 and text).




FIGURE 15.—Chromatin effects on pJFRC2, assayed by R9C11-GAL4. *Drosophila* adult brains were immunostained for GFP. pJFRC2 was integrated in 12 docking sites and crossed to R9C11-GAL4 in *attP2*. The genomic docking site is shown in the top left corner of each panel and the chromosome arm of the insertion site in the top right. With the exception of *VK00026*, all docking sites showed strong, reproducible expression (also see Figure S6 and Figure S7). UAS transgenes seem to be less susceptible to chromatin influence than enhancer-GAL4 constructs; for example, *VK00005* works well for UAS, but not GAL4, insertions (compare with Figure 14; also see Figure S4 and Figure S5).

properties. To identify such a set, we began with 16 PhiC31 genomic *attP* docking sites (Figure 13) and assayed their ability to support (1) expression in the adult nervous system when an enhancer trap vector was inserted, (2) expression driven by an exogenous enhancer, and (3) expression from a UAS construct responding to a GAL4 driver. We tested for criterion 1 by constructing an enhancer detector (O'KANE and GEHRING 1987; BELLEN *et al.* 1990), pBDPGAL4Uw, and integrating it into each of these sites. We crossed lines containing pBDPGAL4Uw with UAS-mCD8::GFP (LEE and LUO 1999) and assayed for GFP in the adult brain (data not shown). In four cases, strong position effects were observed, while the remaining 12 candidate *attP* sites showed minimal or no detectable expression of GFP in the adult brain. We confirmed these results using the stronger GFP reporter pJFRC2 (see Figure S3).

We then tested for the ability of these 12 selected *attP* sites to allow robust expression of GAL4 driven by an enhancer and a strong core promoter, the DSCP promoter (PFEIFFER *et al.* 2008). Of the 12 sites, 2 gave integrants at low efficiency rates and were not analyzed further (Figure 14). We integrated three GAL4 drivers, R9C11, R9B05, and R9D11 (PFEIFFER *et al.* 2008), which have different expression patterns, into the remaining 10 sites and crossed them to pJFRC2 (in *attP2*) to measure reproducibility and fidelity of expression between sites (Figure 14; also see Figure S4 and Figure S5). Five sites (labeled in red in Figure 13) were identified as superior on the basis of their displaying little modification of the expression patterns observed when the three

test drivers were inserted in *attP2*, a site known to support robust expression (MARKSTEIN *et al.* 2008; PFEIFFER *et al.* 2008).

Chromatin environment can influence transgene expression unpredictably, and thus the same genomic landing sites might not work well for both enhancer-driven GAL4 expression and UAS reporters. We therefore also evaluated the 12 sites for their ability to support expression from an integrated UAS construct in response to GAL4. We crossed pJFRC2 integrated into each of the 12 different *attP* genomic sites to three GAL4 drivers (all in *attP2*), see above, to measure pattern fidelity and reliability of expression relative to the same construct inserted in *attP2*. Reproducibility and fidelity of pJFRC2 expression patterns were consistent across 11 of the 12 insertion sites (Figure 15; also see Figure S6 and Figure S7). Unlike enhancer-GAL4 constructs, the UAS transgenes seem more refractory to chromatin influence and thus offer a larger choice for genomic integration sites, an observation also reported by BISCHOF *et al.* (2007). As summarized in Figure 13, by screening 16 different *attP* docking sites we were able to identify 5 sites (labeled in red) that meet all three of our criteria as well as 6 additional sites (labeled in blue) that appear suitable for UAS-effector constructs but not for enhancer-GAL4 constructs.

A subset of genomic *attP* docking sites is flanked with gypsy insulators (N1 *et al.* 2009). Unexpectedly, GFP staining from crosses with GAL4 lines integrated into these sites shows a common background expression in a few cells in the lateral horn in addition to the expected

pattern (Figure 14 and see also Figure S3). To test whether this common background was caused by the insulators themselves, we assayed the ability of the gypsy insulator alone to drive transcription of GAL4. We found that the lateral horn expression seen in docking sites *su(Hw)attP1*, *su(Hw)attP2*, *su(Hw)attP5*, *su(Hw)attP6*, and *su(Hw)attP8* is reproduced when the insulator itself is used as an enhancer (data not shown). In contrast to the GAL4 drivers, UAS effectors integrated into these sites lacked the lateral horn background and showed reproducible expression patterns relative to *attP2*. However, we did not see a significant boost in reporter gene expression levels when either a UAS or GAL4 was inserted in insulated genomic *attP* sites.

DISCUSSION

Many experiments in biological research rely critically on the ability to express exogenous proteins or RNAs in transgenic animals in a manner that is regulated for level, timing, and cell type. Methods that seek to attain that goal in *D. melanogaster* have been developed in a number of laboratories. Although widely used, the characteristics and limitations of these methods have generally not been critically evaluated and are often not appreciated by end users. In the studies we report here, we have attempted to assess different methods, understand the variables that affect their performance, and use that knowledge to improve them.

We first studied the GAL4/UAS binary system (BRAND and PERRIMON 1993; DUFFY 2002). Modifications in codon usage, activation domains, transcriptional terminators, and other features of the UTRs can result in substantial changes in both strength and pattern of expression. Varying the GAL4 activation domain has the single biggest effect on GAL4-driven expression, in terms of both expression level and number of cells observed in the pattern. The choice of GAL4 transcriptional terminator can also effect roughly twofold changes in reporter levels and alter the observed expression pattern, most likely by modifying the half-life of the GAL4 mRNA. We also systematically characterized the effects of promoters, introns, number of UAS-binding sites, tandem copies of UAS constructs, 3'-post-transcriptional modifiers, and protein tags on GFP expression levels from UAS reporter constructs. These data should facilitate optimal construct design for most future GAL4/UAS applications.

The ability to use distinct binary systems to independently target different cells or tissues in the same animal has many applications. The bacterial repressor LexA (BRENT and PTASHNE 1981; LITTLE *et al.* 1981) binds DNA sequences distinct from those recognized by GAL4 and has been successfully used in diverse eukaryotic systems such as yeast (ESTOJAK *et al.* 1995), *Drosophila*

(DIEGELMANN *et al.* 2008), and zebrafish (EMELYANOV and PARINOV 2008). However, the utility of LexA/LexAop as a second binary system in *Drosophila* has been limited by the relative leakiness of the *colE1*-derived binding sites and weakness of the drivers compared to GAL4/UAS. We replaced the published GAL4 deletion (GADd) and VP16 activation domains with an extended GAL4 activation domain (GADf1) and the human p65 activation domain. We also screened LexA-binding sites from a variety of LexA target genes and found that 13 copies of a binding site derived from the *sulA* gene produced robust reporter expression in the presence of LexA, with no expression detectable by histochemical methods in its absence. However, sensitive assays using flippase suggest there may still be a very low level of leak under some circumstances (A. NERN, B. D. PFEIFFER and G. M. RUBIN, unpublished results). Used together, our new LexA drivers and reporter constructs produce similar expression levels and signal-to-noise ratios to those of the GAL4/UAS system.

POTTER *et al.* (2010) reported development of a third binary system for use in *Drosophila* based on the *qa* gene cluster of *Neurospora crassa* (GILES *et al.* 1991). This system shows great promise, but the apparent toxicity of the Q transcription factor (POTTER *et al.* 2010) currently limits its widespread application. Once this issue is addressed, and with the improvements to the LexA system we report here, there will be three independent binary transcriptional activation systems available for use in *Drosophila*.

Even when single enhancers are used to drive GAL4 expression, few resultant patterns will be limited to a single cell type. In many cases, more restricted expression will be desired for use in behavioral, anatomical, or developmental studies. Using Split GAL4 to restrict expression to the overlap between two "parent" enhancers is one attractive option (LUAN *et al.* 2006). However, the low level of expression obtained using the reconstituted GAL4 limited its utility. We were able to increase expression levels significantly by replacing the VP16 activation domain with the stronger activation domain from the human p65 protein.

Another option for refining expression patterns is to block GAL4 activity in regions where its expression overlaps with that of GAL80. GAL80 inhibits transcription of genes under UAS control by binding to a 30-amino-acid region on the C terminus of GAL4 (JOHNSTON *et al.* 1987; MA and PTASHNE 1987b). Two factors have limited the use of this GAL80-based approach. The first is the lack of a method to visualize GAL80 expression, other than by its ability to suppress GAL4 activity. We can overcome this limitation by using an enhancer whose expression pattern has been previously determined by assaying its ability to drive GAL4 (PFEIFFER *et al.* 2008). Taking advantage of the modular nature of the vectors we describe here, we can then use that enhancer to drive GAL80. The second limitation is

the stoichiometric requirement for GAL80. In cases where GAL80 is driven from a strong promoter, such as α -1 tubulin, a single transgene is sufficient to suppress GAL4-mediated transcription (LEE and LUO 1999; VEF *et al.* 2006); however, we found that when GAL4 and GAL80 are driven under the same enhancer, a single copy of GAL80 may be insufficient, especially when the vector utilizes the same, mRNA-destabilizing *hsp70* 3'-UTR as used in the GAL4 constructs. This problem can be fixed by using two copies of GAL80, either by generating a stock bearing GAL80 in two locations or by building a tandem construct with two copies of GAL80 in one insertion. Alternatively, the efficacy of a single copy of GAL80 can be improved by optimizing the codon usage of the *GAL80* gene and including two post-transcriptional regulatory elements thought to increase the efficiency of mRNA transport, an intron and the WPRE. These changes allowed us to completely suppress GAL4 activity with a single copy of GAL80 when the two genes were expressed from the same enhancer in vectors designed to maximize the concurrence of the expression of the two proteins.

The local chromatin environment at the site of transgene insertion can alter both the pattern and the level of transgene expression (SPRADLING and RUBIN 1983; HIROMI *et al.* 1985; KIRKPATRICK *et al.* 1994). MARKSTEIN *et al.* (2008) used luciferase to quantify such position effects in 20 genomic *attP* docking sites and found a wide range of basal and inducible levels of expression. In addition, leakiness and inducibility varied not only across insertion loci, but also between tissues. These effects are not surprising, considering that chromatin changes are involved in tissue-specific gene regulation (SCHULZE and WALLRATH 2007; GIRTON and JOHANSEN 2008). Thus, identification of suitable genomic docking sites relies on empirical testing in the tissues and developmental stages of interest. We assayed for position effects affecting adult brain GFP expression in 16 *attP* genomic docking sites. Although there is no single ideal locus for all transgenes, we identified 5 sites that show reproducible levels of expression for enhancer-GAL4 constructs and 11 for UAS-mCD8::GFP. As far as we have tested, these *attP* sites work well for other driver and responder combinations. These selected sites are also all permissive to integration, making them efficient for the production of transgenic lines.

In the course of this work we identified two areas that require further technology development. First, in a significant minority of driver lines, transgene expression is stochastic; that is, not all cells of a given type express the transgene, and the precise cells showing expression vary from animal to animal. We do not know the underlying cause of this variation, but we speculate that it most likely relates to the difficulty in overcoming chromatin blocks to initiating transcription. This phenomenon has been observed in a wide variety of transgenic systems (see, for example, AHMAD and HENIKOFF

2001; SKORA and SPRADLING 2010). Detecting stochastic expression often requires careful examination and is most easily scored in lines that express in repeating patterns, for example, in a cell type that occurs in each of the 800 cartridges of the lamina or each of the segments of the larval ventral nerve cord. We observed that increasing the strength of the activation domain can reduce this variation; also, certain integration sites in the genome appear to favor more uniform expression. But we have not found a general mechanism to resolve this issue, and at this point we avoid using such lines in experiments that depend on nonstochastic expression, such as measuring the behavioral effects of inactivation of a cell class.

The second issue that has not yet been adequately addressed is intrinsic to any experiment involving expression of an exogenous protein or an endogenous protein at elevated levels: such expression can perturb cell function and cell structure. These effects can be obvious, such as cell death. However, sometimes they are subtle. Here the only solution is to assay the exogenous protein for its intended effects on the cell and use only the minimal level of expression sufficient for the experiment. The tools we have presented—for example, a series of vectors with different numbers of UAS sites—will be useful in achieving the desired expression level and also in normalizing expression levels when using enhancers of different strengths.

In conclusion, we report here an extensive set of experiments in which we empirically tested a wide range of modifications to the vectors and methods commonly used to direct exogenous gene expression in *Drosophila*. We have been able to modulate the level of transgene expression by varying the strength of the activation domain carried by the transcriptional activator as well as the number of copies of its binding site and other properties of the reporter construct. Additional engineering to increase expression levels is not warranted, as significant toxicity appears to result from the exogenous proteins at the high end of our current expression range. We also solved the problem of leakiness of the LexA operator in the absence of LexA protein and made the Split GAL4 and GAL80 intersectional strategies more robust. Given the widespread use of these methods, we expect our results will have considerable utility.

We thank Robin Harris and Aljoscha Nern for thoughtful advice and constructive criticism. We thank Bruce Baker, Robin Harris, Tzumin Lee, Aljoscha Nern, Andrew Seeds, and Julie Simpson for comments on the manuscript; David Anderson for alerting us to the WPRE element; Scott Sternson for FLEX DNA containing the WPRE; Gary Struhl for plasmid G610; Henry Chang for *myr::mRFP* DNA; Chris Potter and Liqun Luo for communicating information about the Q system prior to publication; and Kevin McGowan for the suggestion of the name JFRC. Todd Laverty and the Janelia Farm Fly Core assisted with *Drosophila* genetics and stock maintenance. Rodney Simmons and Rose Rogall provided media and general lab support. Kevin McGowan, Melissa Ramirez, Torrey Gallagher, and Xiaorong Zhang performed DNA sequencing. Susan Zusman, Michael Tworoger, and

GSI, Inc. generated the transgenic lines. Crystal Sullivan provided us with excellent administrative support.

LITERATURE CITED

- ADAMS, M. D., S. E. CELNIKER, R. A. HOLT, C. A. EVANS, J. D. GOCAYNE *et al.*, 2000 The genome sequence of *Drosophila melanogaster*. *Science* **287**: 2185–2195.
- AHMAD, K., and S. HENIKOFF, 2001 Modulation of a transcription factor counteracts heterochromatic gene silencing in *Drosophila*. *Cell* **104**: 839–847.
- ATASOY, D., Y. APONTE, H. H. SU and S. M. STERNSON, 2008 A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping. *J. Neurosci.* **28**: 7025–7030.
- BELLEN, H. J., C. WILSON and W. J. GEHRING, 1990 Dissecting the complexity of the nervous system by enhancer detection. *BioEssays* **12**: 199–204.
- BISCHOF, J., R. K. MAEDA, M. HEDIGER, F. KARCH and K. BASLER, 2007 An optimized transgenesis system for *Drosophila* using germ-line-specific phiC31 integrases. *Proc. Natl. Acad. Sci. USA* **104**: 3312–3317.
- BRAND, A. H., and N. PERRIMON, 1993 Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**: 401–415.
- BRAND, A. H., A. S. MANOUKIAN and N. PERRIMON, 1994 Ectopic expression in *Drosophila*. *Methods Cell Biol.* **44**: 635–654.
- BRENT, R., and M. PTASHNE, 1981 Mechanism of action of the *lexA* gene product. *Proc. Natl. Acad. Sci. USA* **78**: 4204–4208.
- BRENT, R., and M. PTASHNE, 1984 A bacterial repressor protein or a yeast transcriptional terminator can block upstream activation of a yeast gene. *Nature* **312**: 612–615.
- BRENT, R., and M. PTASHNE, 1985 A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. *Cell* **43**: 729–736.
- BUTALA, M., D. ZGUR-BERTOK and S. J. BUSBY, 2008 The bacterial *LexA* transcriptional repressor. *Cell. Mol. Life Sci.* **66**: 82–93.
- CHOI, T., M. HUANG, C. GORMAN and R. JAENISCH, 1991 A generic intron increases gene expression in transgenic mice. *Mol. Cell. Biol.* **11**: 3070–3074.
- COLE, S. T., 1983 Characterisation of the promoter for the *LexA* regulated *sulA* gene of *Escherichia coli*. *Mol. Gen. Genet.* **189**: 400–404.
- DIEGELMANN, S., M. BATE and M. LANDGRAF, 2008 Gateway cloning vectors for the *LexA*-based binary expression system in *Drosophila*. *Fly* **2**: 236–239.
- DUFFY, J. B., 2002 *GAL4* system in *Drosophila*: a fly geneticist's Swiss army knife. *Genesis* **34**: 1–15.
- DUNCKER, B. P., P. L. DAVIES and V. K. WALKER, 1997 Introns boost transgene expression in *Drosophila melanogaster*. *Mol. Gen. Genet.* **254**: 291–296.
- EBINA, Y., Y. TAKAHARA, F. KISHI, A. NAKAZAWA and R. BRENT, 1983 *LexA* protein is a repressor of the colicin E1 gene. *J. Biol. Chem.* **258**: 13258–13261.
- EMELYANOV, A., and S. PARINOV, 2008 Mifepristone-inducible *LexPR* system to drive and control gene expression in transgenic zebrafish. *Dev. Biol.* **320**: 113–121.
- ESTOJAK, J., R. BRENT and E. A. GOLEMIS, 1995 Correlation of two-hybrid affinity data with *in vitro* measurements. *Mol. Cell. Biol.* **15**: 5820–5829.
- FEINBERG, E. H., M. K. VANHOVEN, A. BENDESKY, G. WANG, R. D. FETTER *et al.*, 2008 GFP reconstitution across synaptic partners (GRASP) defines cell contacts and synapses in living nervous systems. *Neuron* **57**: 353–363.
- FIELDS, S., and O. SONG, 1989 A novel genetic system to detect protein-protein interactions. *Nature* **340**: 245–246.
- FISCHER, J. A., E. GINIGER, T. MANIATIS and M. PTASHNE, 1988 *GAL4* activates transcription in *Drosophila*. *Nature* **332**: 853–856.
- GERLITZ, O., D. NELLEN, M. OTTIGER and K. BASLER, 2002 A screen for genes expressed in *Drosophila* imaginal discs. *Int. J. Dev. Biol.* **46**: 173–176.
- GILES, N. H., R. F. GEEVER, D. K. ASCH, J. AVALOS and M. E. CASE, 1991 The Wilhelmine E. Key 1989 invitational lecture. Organization and regulation of the *qa* (quinic acid) genes in *Neurospora crassa* and other fungi. *J. Hered.* **82**: 1–7.
- GIRTON, J. R., and K. M. JOHANSEN, 2008 Chromatin structure and the regulation of gene expression: the lessons of PEV in *Drosophila*. *Adv. Genet.* **61**: 1–43.
- GORDON, M. D., and K. SCOTT, 2009 Motor control in a *Drosophila* taste circuit. *Neuron* **61**: 373–384.
- GROTH, A. C., M. FISH, R. NUSSE and M. P. CALOS, 2004 Construction of transgenic *Drosophila* by using the site-specific integrase from phage phiC31. *Genetics* **166**: 1775–1782.
- GUSTAFSSON, C., S. GOVINDARAJAN and J. MINSHULL, 2004 Codon bias and heterologous protein expression. *Trends Biotechnol.* **22**: 346–353.
- HIROMI, Y., A. KUROIWA and W. J. GEHRING, 1985 Control elements of the *Drosophila* segmentation gene *fushi tarazu*. *Cell* **43**: 603–613.
- HORNE-BADOVINAC, S., and D. BILDER, 2008 Dynein regulates epithelial polarity and the apical localization of stardust A mRNA. *PLoS Genet.* **4**: e8.
- HRDLICKA, L., M. GIBSON, A. KIGER, C. MICCHELLI, M. SCHOBER *et al.*, 2002 Analysis of twenty-four *GAL4* lines in *Drosophila melanogaster*. *Genesis* **34**: 51–57.
- HUANG, M. T., and C. M. GORMAN, 1990 Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA. *Nucleic Acids Res.* **18**: 937–947.
- JOHNSTON, S. A., and J. E. HOPPER, 1982 Isolation of the yeast regulatory gene *GAL4* and analysis of its dosage effects on the galactose/melibiose regulon. *Neuron* **22**: 451–461.
- JOHNSTON, S. A., J. M. SALMERON, JR. and S. S. DINCHER, 1987 Interaction of positive and negative regulatory proteins in the galactose regulon of yeast. *Cell* **50**: 143–146.
- KEEGAN, L., G. GILL and M. PTASHNE, 1986 Separation of DNA binding from the transcription-activating function of a eukaryotic regulatory protein. *Science* **231**: 699–704.
- KIRKPATRICK, R. B., Z. PARVEEN and P. F. MARTIN, 1994 Isolation of silencer containing sequences causing a tissue-specific position effect on alcohol dehydrogenase expression in *Drosophila melanogaster*. *Dev. Genet.* **15**: 188–200.
- KITAGAWA, Y., E. AKABOSHI, H. SHINAGAWA, T. HORII, H. OGAWA *et al.*, 1985 Structural analysis of the *umu* operon required for inducible mutagenesis in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **82**: 4336–4340.
- KRAMER, J. M., and B. E. STAVELEY, 2003 *GAL4* causes developmental defects and apoptosis when expressed in the developing eye of *Drosophila melanogaster*. *Genet. Mol. Res.* **2**: 43–47.
- LAI, S. L., and T. LEE, 2006 Genetic mosaic with dual binary transcriptional systems in *Drosophila*. *Nat. Neurosci.* **9**: 703–709.
- LEE, T., and L. LUO, 1999 Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. *Neuron* **22**: 451–461.
- LEE, Y. S., and R. W. CARTHEW, 2003 Making a better RNAi vector for *Drosophila*: use of intron spacers. *Methods* **30**: 322–329.
- LEWIS, E. B., 1950 The phenomenon of position effect. *Adv. Genet.* **3**: 73–115.
- LITTLE, J. W., and D. W. MOUNT, 1982 The SOS regulatory system of *Escherichia coli*. *Cell* **29**: 11–22.
- LITTLE, J. W., D. W. MOUNT and C. R. YANISCH-PERRON, 1981 Purified *lexA* protein is a repressor of the *recA* and *lexA* genes. *Proc. Natl. Acad. Sci. USA* **78**: 4199–4203.
- LUAN, H., N. C. PEABODY, C. R. VINSON and B. H. WHITE, 2006 Refined spatial manipulation of neuronal function by combinatorial restriction of transgene expression. *Neuron* **52**: 425–436.
- MA, J., and M. PTASHNE, 1987a Deletion analysis of *GAL4* defines two transcriptional activating segments. *Cell* **48**: 847–853.
- MA, J., and M. PTASHNE, 1987b The carboxy-terminal 30 amino acids of *GAL4* are recognized by *GAL80*. *Cell* **50**: 137–142.
- MARKSTEIN, M., C. PITSOULI, C. VILLALTA, S. E. CELNIKER and N. PERRIMON, 2008 Exploiting position effects and the gypsy retrovirus insulator to engineer precisely expressed transgenes. *Nat. Genet.* **40**: 476–483.
- MARLOR, R. L., S. M. PARKHURST and V. G. CORCES, 1986 The *Drosophila melanogaster* gypsy transposable element encodes putative gene products homologous to retroviral proteins. *Mol. Cell. Biol.* **6**: 1129–1134.
- MAUSS, A., M. TRIPODI, J. F. EVERS and M. LANDGRAF, 2009 Midline signaling systems direct the formation of a neural map by den-

- drift targeting in the *Drosophila* motor system. *PLoS Biol.* **7**: e1000200.
- MELCHER, K., 2000 The strength of acidic activation domains correlates with their affinity for both transcriptional and non-transcriptional proteins. *J. Mol. Biol.* **301**: 1097–1112.
- NI, J. Q., M. MARKSTEIN, R. BINARI, B. PFEIFFER, L. P. LIU *et al.*, 2008 Vector and parameters for targeted transgenic RNA interference in *Drosophila melanogaster*. *Nat. Methods* **5**: 49–51.
- NI, J. Q., L. P. LIU, R. BINARI, R. HARDY, H. S. SHIM *et al.*, 2009 A *Drosophila* resource of transgenic RNAi lines for neurogenetics. *Genetics* **182**: 1089–1100.
- NOGI, Y., and T. FUKASAWA, 1984 Nucleotide sequence of the yeast regulatory gene GAL80. *Nucleic Acids Res.* **12**: 9287–9298.
- O'KANE, C. J., and W. J. GEHRING, 1987 Detection in situ of genomic regulatory elements in *Drosophila*. *Proc. Natl. Acad. Sci. USA* **84**: 9123–9127.
- OSTERWALDER, T., K. S. YOON, B. W. WHITE and H. KESHISHIAN, 2001 A conditional tissue specific transgene expression system using inducible GAL4. *Proc. Natl. Acad. Sci. USA* **98**: 12596–12601.
- PEREANU, W., and V. HARTENSTEIN, 2006 Neural lineages of the *Drosophila* brain: a three-dimensional digital atlas of the pattern of lineage location and projection at the late larval stage. *J. Neurosci.* **26**: 5534–5553.
- PERRY, K. L., S. J. ELLEDGE, B. B. MITCHELL, L. MARSH and G. C. WALKER, 1985 umuDC and mucAB operons whose products are required for UV light- and chemical induced mutagenesis: UmuD, MucA, and LexA proteins share homology. *Proc. Natl. Acad. Sci. USA* **82**: 4331–4335.
- PETERSEN, R. B., and S. LINDQUIST, 1989 Regulation of HSP70 synthesis by messenger RNA degradation. *Cell Regul.* **1**: 135–149.
- PFEIFFER, B. D., A. JENETT, A. S. HAMMONDS, T.-T. NGO, S. MISRA *et al.*, 2008 Tools for neuroanatomy and neurogenetics in *Drosophila*. *Proc. Natl. Acad. Sci. USA* **105**: 9715–9720.
- POTTER, C. J., B. TASIC, E. V. RUSSELL, L. LIANG and L. LUO, 2010 The Q system: a repressible binary system for transgene expression, lineage tracing, and mosaic analysis. *Cell* **141**: 536–548.
- PTASHNE, M., 1988 How eukaryotic transcriptional activators work. *Nature* **335**: 683–689.
- RESH, M. D., 1999 Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. *Biochim. Biophys. Acta* **1451**: 1–16.
- ROMAN, G., K. ENDO, L. ZANG and R. L. DAVIS, 2001 P[Switch], a system for spatial and temporal control of gene expression in *Drosophila melanogaster*. *Proc. Natl. Acad. Sci. USA* **98**: 12602–12607.
- SADOWSKI, I., J. MA, S. TRIEZENBERG and M. PTASHNE, 1988 GAL4-VP16 is an unusually potent transcriptional activator. *Nature* **335**: 563–564.
- SALMERON, J. M., JR., S. D. LANGDON and S. A. JOHNSTON, 1989 Interaction between transcriptional activator protein LAC9 and negative regulatory protein GAL80. *Mol. Cell. Biol.* **9**: 2950–2956.
- SALMERON, J. M., JR., K. K. LEUTHER and S. A. JOHNSTON, 1990 GAL4 mutations that separate the transcriptional activation and GAL80-interactive functions of the yeast GAL4 protein. *Genetics* **125**: 21–27.
- SCHMITZ, M. L., and P. A. BAEUERLE, 1991 The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. *EMBO J.* **10**: 3805–3817.
- SCHNARR, M., P. OERTEL-BUCHHEIT, M. KAZMAIER and M. GRANGER-SCHNARR, 1991 DNA binding properties of the LexA repressor. *Biochimie* **73**: 423–431.
- SCHULZE, S. R., and L. L. WALLRATH, 2007 Gene regulation by chromatin structure: paradigms established in *Drosophila melanogaster*. *Annu. Rev. Entomol.* **52**: 171–192.
- SHANG, Y., L. C. GRIFFITH and M. ROSBASH, 2008 Light-arousal and circadian photoreception circuits intersect at the large PDF cells of the *Drosophila* brain. *Proc. Natl. Acad. Sci. USA* **105**: 19587–19594.
- SKORA, A. D., and A. C. SPRADLING, 2010 Epigenetic stability increases extensively during *Drosophila* follicle stem cell differentiation. *Proc. Natl. Acad. Sci. USA* **107**: 7389–7394.
- SMITH, A. E., D. KALDERON, B. L. ROBERTS, W. H. COLLEDGE, M. EDGE *et al.*, 1985 The nuclear location signal. *Proc. R. Soc. Lond. B Biol. Sci.* **226**: 43–58.
- SPANAN, C., D. A. HARRISON and V. G. CORCES, 1988 The *Drosophila* melanogaster suppressor of Hairy-wing protein binds to specific sequences of the gypsy retrotransposon. *Genes Dev.* **2**: 1414–1423.
- SPRADLING, A. C., and G. M. RUBIN, 1983 The effect of chromosomal position on the expression of the *Drosophila* xanthine dehydrogenase gene. *Cell* **34**: 47–57.
- STOLERU, D., Y. PENG, J. AGOSTO and M. ROSBASH, 2004 Coupled oscillators control morning and evening locomotor behaviour of *Drosophila*. *Nature* **431**: 862–868.
- SUSTER, M. L., L. SEUGNET, M. BATE and M. B. SOKOLOWSKI, 2004 Refining GAL4 driven transgene expression in *Drosophila* with a GAL80 enhancer-trap. *Genesis* **39**: 240–245.
- SZÜTS, D., and M. BIENZ, 2000 LexA chimeras reveal the function of *Drosophila* Fos as a context-dependent transcriptional activator. *Proc. Natl. Acad. Sci. USA* **97**: 5351–5356.
- TRAVEN, A., B. JELICIC and M. SOPTA, 2006 Yeast Gal4: a transcriptional paradigm revisited. *EMBO Rep.* **7**: 496–499.
- TRUMAN, J. W., H. SCHUPPE, D. SHEPHERD and D. W. WILLIAMS, 2004 Developmental architecture of adult-specific lineages in the ventral CNS of *Drosophila*. *Development* **131**: 5167–5184.
- VEF, O., D. CLEPPIN, T. LÖFFLER, B. ALTENHEIN and G. M. TECHNAU, 2006 A new strategy for efficient in vivo screening of mutagenized *Drosophila* embryos. *Dev. Genes Evol.* **216**: 105–108.
- VENKEN, K. J., Y. HE, R. A. HOSKINS and H. J. BELLEN, 2006 P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in *D. melanogaster*. *Science* **314**: 1747–1751.
- VILLALOBOS, A., J. E. NESS, C. GUSTAFSSON, J. MINSHULL and S. GOVINDARAJAN, 2006 Gene Designer: a synthetic biology tool for constructing artificial DNA segments. *BMC Bioinformatics* **7**: 285.
- WADE, J. T., N. B. REPPAS, G. M. CHURCH and K. STRUHL, 2005 Genomic analysis of LexA binding reveals the permissive nature of the *Escherichia coli* genome and identifies unconventional target sites. *Genes Dev.* **19**: 2619–2630.
- WALKER, G. C., 1984 Mutagenesis and inducible responses to deoxyribonucleic acid damage in *Escherichia coli*. *Microbiol. Rev.* **48**: 60–93.
- WEBSTER, N., J. R. JIN, S. GREEN, M. HOLLIS and P. CHAMBON, 1988 The yeast UAS_G is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator. *Cell* **52**: 169–178.
- WILSON, C., H. J. BELLEN and W. J. GEHRING, 1990 Position effects on eukaryotic gene expression. *Annu. Rev. Cell Biol.* **6**: 679–714.
- YUN, S. J., Y. HIRAOKA, M. NISHIZAWA, K. TAKIO, K. TITANI *et al.*, 1991 Purification and characterization of the yeast negative regulatory protein GAL80. *J. Biol. Chem.* **266**: 693–697.
- ZIELER, H., and C. Q. HUYNH, 2002 Intron-dependent stimulation of marker gene expression in cultured insect cells. *Insect Mol. Biol.* **11**: 87–95.
- ZUFFEREY, R., J. E. DONELLO, D. TRONO and T. J. HOPE, 1999 Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. *J. Virol.* **73**: 2886–2892.

GENETICS

Supporting Information

<http://www.genetics.org/cgi/content/full/genetics.110.119917/DC1>

Refinement of Tools for Targeted Gene Expression in *Drosophila*

**Barret D. Pfeiffer, Teri-T B. Ngo, Karen L. Hibbard, Christine Murphy, Arnim Jenett,
James W. Truman and Gerald M. Rubin**

Copyright © 2010 by the Genetics Society of America
DOI: 10.1534/genetics.110.119917




FIGURE S1.—Effects of SV40 terminators on GAL4-driven GFP expression. *Drosophila* adult brains immunostained for GFP. Different GAL4 drivers directed by enhancers R9B05, R9C11, and R9D11 were crossed to pJFRC2-10XUAS-IVS-mCD8::GFP. All constructs integrated into *attP2*. (A), (C), and (E), GAL4 constructs with an *hsp70* terminator and yeast GAL4 (PFEIFFER *et al.* 2008). (B), (D), and (E), Codon-optimized GAL4 with an SV40 terminator, and with the *hsp70* 5' UTR sequences and yeast transcriptional terminator removed.




FIGURE S2.—Cell damage caused from excessive expression of responder proteins. *Drosophila* third instar larvae were immunostained for GFP and a dorsal view of the thoracic VNC is shown. With the exception of the 5XUAS-mCD8::GFP (LEE and LUO 1999) construct all transgenes are integrated into *attP2*. CRM R9C11 was used to direct expression of three GAL4 variants: standard GAL4 (as used in the constructs described by PFEIFFER *et al.* 2008), GAL4.2::VP16, or GAL4.2::p65. These three GAL4 drivers were crossed to different responders as indicated, which vary in number of UAS sites and localization tag: (A-C) 5XUAS-mCD8::GFP of LEE and LUO (1999). (D-F) 10XUAS-mCD8::GFP (pJFRC2). (G-I) 10XUAS-myr::GFP (pJFRC12): myristoylated, codon-optimized GFP. (J-L) 20XUAS-mCD8::GFP (pJFRC7). CRM R9C11 drives strong expression in a pair of medial thoracic interneurons; each sends a primary neurite across the midline that then bifurcates (arrow) to produce prominent anterior- and posterior-directed arbors. These arbors look normal in all cases when the driver is GAL4. With the VP16 activation domain, neurons that were apparently below our detection threshold with the GAL4 driver begin to become obvious using the pJFRC responders and expression in the medial interneurons is diminished in the 20XUAS relative to the 10XUAS responder. With the p65 activation domain, the line with the 5XUAS driver appears normal, but with higher UAS copy number (F,I,L) the large medial interneuron is no longer evident [arrows point to its expected location] and the expression in the formerly weak neurons is quite prominent.




FIGURE S3.—Assay for position effects across 16 *attP* sites. *Drosophila* adult brains immunostained for GFP. We assayed 16 genomic *attP* sites for position effects using an enhancer detector, pBDPGAL4U (PFEIFFER *et al.* 2008), containing a minimal basal promoter, DSCP, and GAL4. These detectors were crossed to pJFRC2 in *attP2*. Any enhancers in the local chromatin environment act on pBDPGAL4U and direct cell-specific GFP expression, as observed with *VK00016*, *attP16*, *attP1*, and *su(Hw)attP4*. These sites were rejected. The remaining twelve sites showed little to no GFP expression and were investigated further. Ectopic GFP expression caused by the gypsy insulator is present in a set of cells in the lateral horn (blue arrows) in *su(Hw)attP* sites (NI *et al.* 2009; this study).




FIGURE S4.—Chromatin effects on R9B05-GAL4. *Drosophila* adult brains immunostained for GFP. R9B05-GAL4 was integrated into ten *attP* docking sites and crossed to pJFRC2 in *attP2*. The genomic docking site is shown in the upper left corner of each panel and the chromosome arm of the insertion site in the upper right. We were unable to get transformants in the *attP3* and *VK00026* sites. The same sites gave acceptable results as observed with R9C11 (see Figure 15).




FIGURE S5.—Chromatin effects on R9D11-GAL4. *Drosophila* adult brains immunostained for GFP. R9D11-GAL4 was integrated into ten *attP* docking sites and crossed to pJFRC2 in *attP2*. The genomic docking site is shown in the upper left corner of each panel and the chromosome arm of the insertion site in the upper right. We were unable to get transformants in the *attP3* and *VK00026* sites. The same sites gave acceptable results as observed with R9C11 (see Figure 15).




FIGURE S6.—Chromatin effects on pJFRC2, assayed by R9B05-GAL4. *Drosophila* adult brains immunostained for GFP. pJFRC2 was integrated in twelve docking sites and crossed to R9B05-GAL4 in *attP2*. The genomic docking site is shown in the upper left corner of each panel and the chromosome arm of the insertion site in the upper right. The same sites gave acceptable results as observed with R9C11 (see Figure 15).




FIGURE S7.—Chromatin effects on pJFRC2, assayed by R9D11-GAL4. *Drosophila* adult brains immunostained for GFP. pJFRC2 was integrated in twelve docking sites and crossed to R9D11-GAL4 in *attP2*. The genomic docking site is shown in the upper left corner of each panel and the chromosome arm of the insertion site in the upper right. The same sites gave acceptable results as observed with R9C11 (see Figure 15).